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Inhibitors of the activation of platelet aggregation have promise as important therapeutic 
agents for the management of acute coronary syndrome. Platelet activation by thrombin 
occurs by binding to and cleavage of the extracellular N-terminal domains of protease-
activated receptors 1 and 4 (PAR1 and PAR4). The proteolysis of the PARs exposes new 
tethered ligands that then signal through transmembrane domains to initiate platelet 
activation. A pentapeptide cleavage product of bradykinin with the sequence Arg-Pro-
Pro-Gly-Phe (RPPGF) serves as an inhibitor of α- and γ-thrombin-induced platelet 
aggregation.  
Analogs of RPPGF were prepared that result in improved inhibition of thrombin 
activation of platelets. Specific amino acid residues required for activity against platelet 
aggregation have been identified, and a lead compound, D-Arg-Oic-Pro-D-Ala-Phe(p-
Me)-NH2 (27), has been developed. Compound 27, which completely inhibits threshold 
γ-thrombin-induced platelet aggregation at a concentration of 16 µM, represents an 
important lead compound in the development of inhibitors of thrombin-mediated platelet 
aggregation.  
The mechanism of action of compound 27 was studied, and there is a clear 
interaction with the active site of thrombin, as well as preliminary results that indicate 
analog 27 is binding to PAR1. In addition, due to its composition of unnatural amino acid 
residues, 27 is orally available with 12.7% bioavailability in rat models. In order to 
xvii  
 
improve upon this bioavailability, a new series of peptides with modified N- and C-
termini, di-substituted phenylalanine, and methylated arginine analogs designed to reduce 
the net charge and/or increase the lipophilicity of the peptide was prepared. 
 These modifications were well tolerated and a new lead compound was 
discovered. Compound 48 (D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH-Et) has the same 
amino acid sequence as analog 27, but possesses an ethyl group at the amide of the C-
terminus. This compound is a 3-fold more potent inhibitor of thrombin and platelet 
aggregation than is 27 (Ki = 2.1 µM, IC100 = 5 µM). This dissertation has shown the 
benefits of substituting unnatural amino acid residues into the sequence of a naturally 
occurring peptide as a means of modulating activity and developing analogs with 
desirable pharmacokinetic profiles. Compounds 27 and 48 demonstrate promise to 







The development of safe and effective treatment options for thrombotic disorders has 
proven elusive for over half a century. The problem certainly lies in the complexity of the 
hemostatic system, which maintains the balance between thrombus formation and blood 
flow primarily through the action of a serine protease known as thrombin. Inhibition of 
this enzyme would be beneficial for the treatment and prevention of a multitude of 
diseases including acute myocardial infarction, the leading cause of death in the United 
States. Currently available treatments are plagued with side effects, dosage maintenance 
difficulties, and undesirable delivery methods. Consequently, there is great medicinal 
potential for the design and synthesis of a novel anticoagulant agent that is both potent 
and selective with minimal side effects. 
 
MEDICAL BENEFITS OF ANTICOAGULANT THERAPY. Perhaps the most 
promising application of a novel anticoagulant agent would be as a means of preventing 
acute coronary syndrome (ACS). ACS refers to a number of conditions that arise from 
myocardial ischemia, which most often develops as a result of reduced blood supply due 
to ruptured atherosclerotic plaque in the coronary artery of the heart[1, 2]. ACS covers a 
spectrum of clinical conditions ranging from unstable angina to acute myocardial 
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infarction. Acute myocardial infarction (AMI) is the leading cause of death for both men 
and women in the United States comprising 36.3% of all deaths in 2004[3]. AMI refers to 
the rapid development of myocardial necrosis often resulting from plaque rupture with 
thrombus formation in a coronary vessel. This leads to an acute reduction of blood supply 
to a portion of the myocardium[1, 2]. Every year an estimated 1.7 million Americans suffer 
a heart attack of which approximately 90% result from an acute thrombus that obstructs 
an atherosclerotic coronary artery[1, 4]. Therefore, by modulating the activity of the 
hemostatic system, we can attempt to treat and prevent these serious and often fatal 
medical conditions. 
 Venous thromboembolism (VTE) is a collective term used to describe a number 
of medical conditions that result from abnormal thrombosis including deep vein 
thrombosis (DVT) and pulmonary embolism. The incidence rate of VTE in Caucasians 
exceeds 1 in 1,000 persons in the United States with the risk of occurrence increasing to 1 
in 100 for those over the age of 75 years[5-7]. VTE is caused by three major factors: blood 
hypercoagulability (excessive clotting), blood-flow stasis (immobility), and vessel wall 
damage (atherosclerosis)[5]. Anticoagulant treatment is absolutely required in order to 
maintain proper blood circulation in patients with predisposition for these conditions, 
those who have suffered from trauma and/or immobilization, and those on certain 
medications including hormone replacement therapy[8]. Current available treatments 
require constant clinical monitoring due to the variation in individual response to the 
drugs[9]. A new generation of anticoagulants could potentially revolutionize the treatment 
options for thrombotic disorders. 
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 The third major cause of death in the Western world is stroke with 700,000 cases 
each year in the United States[10, 11]. Stroke occurs when the blood supply to a region of 
the brain is interrupted leading to sudden loss of neuronal function and subsequent cell 
death. Approximately 15-25% of all strokes are associated with abnormalities in the 
cardiovascular system causing the formation of a secondary embolus that reaches the 
cerebral circulation resulting in ischemia and neuronal damage[12, 13]. Cardioembolic 
strokes are often treatable with anticoagulants following atrial fibrillation, intracardial 
thrombus or endocarditis[14]. Consequently, the development of a safe and effective 
anticoagulant has the potential of treating stroke by reducing the incidence of detached 
thrombi in patients with high risk factors such as race, hypertension, diabetes, and high 
cholesterol levels[15].        
 
HEMOSTASIS. A thorough understanding of the hemostatic system is essential in order 
to design and develop a new anticoagulant agent. The hemostatic system refers to the 
complex assembly in which serine proteases gather at the cell membrane receptors where 
they arrange into complexes with cofactors leading to a series of regulated enzymatic 
reactions[16, 17]. The final product is a hemostatic thrombus or plug that halts the bleeding 
at the site of damaged endothelium. The hemostatic system spurs into action through the 
activation of two distinct responses: the activation of the factor VII-tissue factor complex 
and the aggregation of circulating platelets[16, 17]. The two responses combined produce 
the hemostatic plug, which is composed of aggregated platelets and deposited fibrin. The 
regulation of these distinct responses requires coordination between the platelet and 
coagulation activation pathways, and such coordination is achieved through the 
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employment of the plasma protease, thrombin[18]. Thrombin is the vital link between 
these two systems.  
 
THROMBIN AND THE COAGULATION SYSTEM. Thrombin, a serine protease 
containing 308 amino acids, is the main effector protease of the coagulation system, 
which includes a series of zymogen transformations culminating in the conversion of 
soluble fibrinogen into insoluble fibrin[19]. Biological amplification is achieved by 
converting substrates (zymogens) into active serine proteases, which then serve as 
enzymes in the next reaction in the cascade. The series of reactions that comprise blood 
coagulation is initiated by the activation of the factor VIIa-tissue factor complex that in 
turn activates factor IX to IXa in the presence of factor VIII (see Figure 1).  Factors IXa 
and VIIIa assemble in a complex known as tenase in order to activate factor X to factor 
Xa[16, 20].  Factor Xa assembles with factor V in the prothrombinase complex to convert 
prothrombin into thrombin. Thrombin then converts soluble fibrinogen to a fibrin clot. If 
there is a need for more thrombin, thrombin can activate factor XI to factor XIa that then 
activates factor IX, amplifying the system. Thrombin generates fibrin deposits at sites of 















Figure 1: Review of the hemostatic system[16]. 
 
As alluded to above, thrombin is a serine protease activated by the cleavage of 
prothrombin in a series of proteolytic activations of several zymogens. After cleavage, 
the newly formed enzyme has an overall ellipsoid-like structure, and is composed of a 
small A-chain and a catalytic B-chain[20, 22]. The catalytic triad of thrombin consists of the 
characteristic residues His, Asp, and Ser that are located at the canyon-like cleft of the 
catalytic pocket[20, 23]. However, thrombin’s catalytic activity is not only dictated by the 
catalytic site, but also by recognition sites involved in regulating the specificity of the 
enzyme for its various substrates. There are two recognition sites that play central roles in 
the function of thrombin: the fibrinogen recognition site (exosite I) and the heparin-
binding site (exosite II). Exosite I consists of the loop Arg67-Ile82 of the B-chain and helps 
in the recognition of the substrate fibrinogen along with thrombomodulin and protease-
activated receptor 1 (PAR1)[19, 20]. Exosite II is the glycosaminoglycan binding site of 
thrombin located at the C-terminus of the B-chain, which binds to glycoprotein Ib and 
heparin, a thrombin inhibitor[19, 20]. Understanding of the interactions between thrombin 
and its substrate is crucial in the identification and design of novel medicinal agents that 
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would interact and modulate the activity of the enzyme. Figure 2 illustrates the active site 
of thrombin along with both recognition sites. 
 
Figure 2: Surface representation of thrombin with HCII bound at the active site. The colors represent the 
electrostatic potential with blue representing positive charge and red denoting negative charge[19]. 
 
 
An important aspect of thrombin action in the hemostatic system is that it has both 
anticoagulant and pro-coagulant activity. In the absence of injury or stimulation, 
endothelial cells in the intravascular compartment are an anticoagulant surface that 
ensures the fluidity of the circulating blood as well as limit intravascular coagulation[16, 
24]. Two systems are primarily responsible for regulating thrombin anti- and pro-
coagulant activity. The first system, protein C and protein S, provides an indirect 
approach to the regulation of thrombin activity. Protein C, a vitamin-K dependent 
protein, is activated by thrombin on endothelial cell membranes by binding of both 
proteins to an endothelial cell protein, thrombomodulin[16, 24-26]. Activated protein C 
(APC) acts as an inhibitor of factors Va and VIIIa, two cofactors of thrombin, thus 
decreasing the rate of thrombin formation[16, 24]. Protein S acts as a cofactor for APC, 
serving as APC’s receptor to localize its inhibitory activity[25]. Initially, thrombin 
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generation in the intravascular compartment results in protein C activation, limiting the 
amount of thrombin formed. Thus thrombin initially acts as an anticoagulant. However, 
the anticoagulant function of thrombin is limited by a finite number of thrombomodulin 
binding sites. If the amount of thrombin exceeds the number of thrombomodulin binding 
sites, then thrombin becomes a physiologic pro-coagulant enzyme[26]. Figure 3 depicts the 
activation and inhibitory action of the protein C and protein S anticoagulant system. 
 
[16]Figure 3: The protein C and protein S anticoagulant system . 
The second c ity is the plasma 
serine 
 
 anticoagulant system that regulates thrombin a tiv
protease inhibitor (SERPIN) simply known as antithrombin (AT). This protein 
operates by directly interacting with the active site of thrombin as well as the other major 
coagulation enzymes (factors Xa, VIIa, IXa, XIa, XIIa, and plasma kallikrein)[19, 25]. AT 
primarily inhibits factors Xa and VIIa, obstructing the formation of both the tenase and 
prothrombase complexes, the two critically important kinetic platforms for physiologic 
activation of the coagulation system. A cofactor for antithrombin activity is heparin, 
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which renders the inhibitor 1,000-fold more potent when it is present[16, 25]. Thrombin is 
also regulated by a second SERPIN, heparin cofactor II. This latter protein is a specific 
thrombin inhibitor whose activity is potentiated by the glycosaminoglycan, dermatan 
sulfate.  
Thrombin also has an important role in platelet activation and aggregation by 
initiatin
AR FAMILY AND ITS INTRACELLULAR SIGNALING. The protease-activated 
g a wide range of platelet responses such as shape change, release of granules, 
mobilization of adhesion molecules (P-selectin) to the platelet surface, and activation of 
glycoprotein (GP) IIb/IIIa and GP Ib[27-29]. Thrombin has two substrates on human 
platelets, protease-activated receptors 1 and 4, that when stimulated lead to platelet 
activation. Thrombin’s interaction with these proteins is an enzyme-substrate interaction 
like the enzyme’s interaction with other proteins. Platelets play a key role in the 
development of acute myocardial syndrome and coronary artery occlusion due to their 
ability to aggregate in large numbers at the site of injury[2, 30].  
 
P
receptors (PARs) were identified as G protein-coupled receptors that use an unusual 
mechanism to convert an extracellular proteolytic cleavage event into a transmembrane 
signal. These receptors carry their own ligand, which remains cryptic until the receptor is 
cleaved by thrombin[31-33]. Figure 4 depicts the activation of the PAR family by thrombin. 
This family includes four receptors known as PAR1, PAR2, PAR3, and PAR4, three of 
which (PAR1, PAR3, and PAR4) are cleaved by thrombin while PAR2 is cleaved by 
trypsin and tryptase[34]. PAR2 is a receptor expressed in the gastrointestinal tract that 
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once activated leads to smooth muscle contraction and release of prostaglandin 
suggesting a role in gastric motility[35]. 
 
 
Figure 4: Mechanism of PAR1 and PAR4 activation by thrombin[34, 36]. 
 
PAR1 and PAR4 are found on the surface of human platelets and are the main 
mediators of thrombosis, while PAR3 serves solely as a facilitator of the cleavage of 
PAR4 in murine cells[27, 34, 37-39]. PAR4 differs from PAR1 in the lack of a downstream 
hirudin-like domain that is important for the interaction with the anion-binding exosite I 
of thrombin[40, 41]. Since PAR4 does not contain this consensus sequence for thrombin 
binding, PAR1 binds more tightly to thrombin and 100-fold lower concentration of the 
latter is necessary for activation compared to PAR4[34, 40-42]. On the other hand, PAR3 
contains the consensus sequence for thrombin binding, indicating that it can bind to the 
enzyme and when paired with PAR4 may help modulate its activity[33, 43]. It has been 
shown that PAR1 and PAR4 do not play redundant roles during platelet activation, but 
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rather complement each other’s response. PAR1 generates the initial response at 
nanomolar concentrations of thrombin while PAR4 maintains the signal once the 
concentration has diminished[39, 44].  
In addition to the presence or absence of the upstream thrombin binding domain, 
the amino acid sequence surrounding the cleavage site of PAR1 and PAR4 are also 
completely different. The PAR1 cleavage site resides at the Arg41-Ser42 peptide bond and 
leads to the unveiling of a new N-terminus with a starting sequence of 42SFLLRN47 
(Figure 5). This sequence represents the tethered ligand that binds intramolecularly to the 
second extracellular loop of the receptor[44]. In contrast, PAR4 is cleaved by thrombin at 
the Arg47-Gly48 peptide bond revealing an N-terminus segment with the sequence 
48GYPGQV53 that serves as the PAR4 tethered ligand[44]. 
 
Figure 5: Structure and features of PAR1 highlighting domains thought to be involved in receptor 
activation and interactions with thrombin[34]. 
 
The stimulation of PAR1/PAR4 at the surface of platelets produces an 
intracellular response that is initiated by the cleavage of the receptor by thrombin. Once 
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activated, PARs can couple to several G proteins thereby triggering a signaling cascade 
resulting in marked changes in the phenotype of the platelet, including cell shape, 
secretion, integrin activation, metabolism, transcription, and cell motility[32, 43]. PAR1 
couples to several G proteins (Gq, Gi, and G12/13) and the cascade responsible for the 
changes in the cellular phenotype is depicted in Figure 6. PAR signaling upregulates 
adhesion molecules expression and triggers the production of active neutrophils and 
monocytes[31]. This event leads to the binding, rolling, and final attachment of platelets 
and leukocytes to the endothelium surface, which may trigger further production of 
thrombin (positive feedback loop) due to the presence of leukocyte tissue factors on the 
surface of these cells[31]. Thrombin also increases the permeability of the endothelium 
surface; therefore, PAR activation triggers edema formation[31].  This system could 
certainly trigger intravascular thrombosis and local tissue damage from leukocyte 
products[31]. Consequently, the inhibition of the PAR1/PAR4 system would be highly 
beneficial for the treatment of several conditions that are propagated by platelet activation 
leading to aggregation and subsequent occlusion of the vascular system, e.g. acute 
coronary syndrome, thrombotic embolism, and/or stroke.  
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Figure 6: Thrombin receptor (PAR1) signaling[36]. 
  
The cleavage of PAR1 and PAR4 are irreversible proteolytic events that if left 
unregulated could result in physiological damage. Therefore, mechanisms are in place for 
modulating the inactivation of these receptors. The first pathway involves cellular 
processing that leads to internalization through coated pits in the plasma membrane and 
succeeding degradation by lysosomes[45]. The second pathway relies on the action of 
plasmin, which is found at high concentrations on the surface of activated platelets[46, 47]. 
Plasmin apparently recognizes the activated receptor and cleaves at a cluster of arginine 
and lysine residues of the tethered ligand thereby deactivating the receptor[47]. The two 
mechanisms may be cell specific, but are both efficient means of inactivation of PAR1 
and PAR4.   
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CURRENT TREATMENTS FOR THROMBOSIS. Two main approaches have been 
employed to prevent and treat thromboembolic disorders: hindering thrombin formation 
and inhibiting the enzyme’s activity. Since the 1940s, vitamin-K antagonists such as 
coumarin, dicoumarol, and warfarin have been the most commonly administered 
anticoagulants for the treatment of a variety of thrombotic conditions. These agents work 
by inhibiting several clotting factors of the coagulation system since they interfere with 
vitamin-K dependent post-translational protein modifications that are essential for their 
function[5]. Therefore, vitamin K antagonists work indirectly by inhibiting the proper 
synthesis of coagulation factors that are necessary to activate thrombin[48]. Warfarin’s 
activity is plagued with inconsistency due to the irregularity of vitamin-K levels in 
individual patients. In addition, it has a narrow therapeutic range requiring constant 
monitoring in order to achieve the most effective dosage[48].  
 A more direct approach to prevent thrombotic disorder involves heparin, a 
sulfated glycosaminoglycan produced by mast cells, that acts by activating antithrombin, 
which in turn inhibits thrombin and coagulation factor Xa[49-51]. Heparin produces a 
conformational change in the endogenous inhibitor that leads to 1,000-fold increase in the 
rate of antithrombin activity[48-50]. There are several drawbacks to the use of heparin 
including poor subcutaneous absorption, variable effect due to binding to multiple plasma 
proteins, and the development of thrombocytopenia (decrease in normal levels of 
platelets)[5, 48, 52]. Smaller fragments of the anticoagulant, known as low-molecular weight 
heparin (LMWH), have been synthesized in an effort to improve the bioavailability and 
hinder interactions with plasma proteins. LMWHs demonstrate greater duration of 
anticoagulant activity and their response appears to correlate with body weight permitting 
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administration of a fixed dose[52]. However, the large size of even these fractions of 
heparin is still a concern since LMWHs must be administered subcutenously limiting 
their use for outpatient therapy[48, 52]. 
 The need to develop an anticoagulant with a high efficacy-to-safety profile has 
lead researchers to explore other means of achieving their goal of efficiently inhibiting 
thrombin with minimal side effects. A new approach involves targeting both the active 
site and the substrate recognition sites of the enzyme and developing what is known as 
direct thrombin inhibitors (DTIs). The advantages of this new class of anticoagulants are 
that they act independently of antithrombin, they do not bind to plasma proteins, and they 
pose no risk of developing thrombocytopenia since DTIs are designed to interact with the 
enzyme only[48]. Hirudin, a 65-amino acid polypeptide extracted from medicinal leeches, 
is a bivalent DTI that interacts with both exosite I and the active site of thrombin, as 
confirmed by both kinetics and x-ray crystallography[9, 53-55]. Hirudin is an extremely 
potent and selective thrombin inhibitor with a Ki value of 20 fM that forms a nearly 
irreversible bond with the enzyme[54].  
Various analogs of hirudin have been synthesized in order to reduce the size of 
the inhibitor and to improve the reversibility of the interaction between drug and enzyme. 
Bivalirudin is a synthetic analog composed of 20-amino acid residues that acts as a 
selective and reversible inhibitor of thrombin. In this analog, both size and reversibility 
are circumvented due to the smaller size and the presence of an amino-terminal D-Phe-
Pro-Arg-Pro sequence, that once bound to the enzyme, is cleaved freeing up the active 
site (i.e. it acts as a substrate)[56-58]. Bivalirudin has been approved by the FDA for use as 
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an anticoagulant for the treatment of unstable angina. However, problems with parenteral 
delivery and rapid clearance have limited its use for a wider range of conditions.    
 A second class of DTIs has produced several promising agents with favorable 
delivery, clearance, and safety profiles as compared to current treatments. These 
univalent DTIs interact solely with the active site of thrombin in a non-covalent fashion 
and are often small molecules. The most notable compound is melagatran, which 
represents a new class of thrombin inhibitors that are reversible, potent, and have a 
molecular mass of 500 Da or less[5, 48, 58-60]. With a Ki value of 2 pM, melagatran is a very 
potent DTI that has some additional functions including its ability to inhibit thrombin-
induced platelet aggregation and it has a wide therapeutic window without unwanted 
bleeding[5, 59]. However, melagatran is unsuitable for oral administration due to low oral 
bioavailability in man, which is associated with the presence of three charged groups in 
the molecule (see Figure 7)[61, 62].  
A prodrug of melagatran (ximelagatran) was synthesized with a hydroxyl group 
attached to the amidine and an ethyl group attached to the carboxylic acid as shown in 
Figure 7. Despite its 185-fold decrease in antithrombin activity, ximelagatran is readily 
converted to melagatran after intestinal absorption and has the potential to be the first oral 
direct thrombin inhibitor[61, 62]. Ximelagatran is currently in Phase III Clinical Trials 
where adverse side effects have been discovered involving increased levels of alanine 
transaminase in the liver after long-term treatment[63-65]. More analogs of this prodrug are 























Figure 7: Structure of melagatran and its prodrug ximelagatran. 
 
 
  In parallel to the development of direct thrombin inhibitors, research has focused 
on another method to selectively target the hemostatic system without interfering with the 
coagulation process. A new class of inhibitors has been designed to interact with 
protease-activated receptors at the surface of platelets. Most of the work thus far has 
focused on PAR1, also known as the thrombin receptor, and several ways of inhibiting 
the signaling at the receptor are being explored. The first and most commonly used 
approach is to design antagonists that compete for binding with the tethered ligand[66-68]. 
Development of PAR1 antagonists began with structural analogs of SFLLRNP (the 
portion of the tethered ligand that interacts with the second extracellular loop of the 
receptor) and have since evolved into small molecules with low nanomolar Ki values and 
potential for oral delivery[68-74].  
 An alternative and novel method of inhibiting PAR1 would be to interfere with 
the docking of thrombin and subsequent cleavage of the receptor. This mechanism of 
action would provide a way to inhibit the activation of not only PAR1, but also other 
members of the PAR family (e.g. PAR3/PAR4) since the potential compound would not 
be designed after the tethered ligand, which varies for each individual receptor. Our 
research focuses on designing and synthesizing such compounds and elucidating this 
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novel mechanism of action. The starting point of our design was previously reported 
work that claimed that plasma kininogens and their cleavage product, bradykinin, both 
possessed antithrombin activity and bound to the surface of platelets preventing thrombin 
from binding to the receptor[75-79]. 
 
BRADYKININ AND RPPGF PEPTIDE. Bradykinin, a nonapeptide, is released from 
the plasma protein high and low molecular weight kininogen through the action of 
plasma kallikrein[76]. Bradykinin increases vascular permeability, dilates blood vessels, 
contracts non-vascular smooth muscle, and causes pain[77]. The short-lived vasodilator is 
further degraded by angiotensin-converting enzyme (ACE) to produce a pentapeptide 
with sequence Arg-Pro-Pro-Gly-Phe (RPPGF)[79]. This pentapeptide, along with 
kininogen and bradykinin, inhibits thrombin-induced platelet activation and aggregation 
by interacting with the active site of thrombin at high concentrations (Ki = 1.7 mM)[80, 81]. 
RPPGF also binds to the extracellular fragment of PAR1 thereby preventing thrombin 
from binding and cleaving PAR1 leading to the inhibition of platelet aggregation[80]. 
Therefore, RPPGF is a formidable lead in the development of a potent inhibitor of 
platelet aggregation. 
 Modifications made to the sequence of RPPGF are the main focus of Chapter II 
and the first portion of Chapter IV of this written work. The structure activity driven 
changes led to the design and synthesis of an analog with 135-fold improvement in the 
activity against thrombin-induced platelet aggregation. This novel lead peptide, 
compound 48 [D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH-Et], is active at 5 µM concentration 
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and shows promise as an orally dosed anticoagulant as described in the final portion of 
Chapter IV.   
 
ORAL DELIVERY AND PEPTIDE THERAPEUTICS. The long-term objective of 
this project is to develop an orally bioavailable drug for treatment of individuals with 
thrombin disorders including acute coronary syndromes. Many of the agents routinely 
used as anticoagulant and/or antiplatelet agents, such as heparin and bivalirudin, are 
administered subcutaneously or intravenously[48]. The only oral anticoagulant currently 
approved to treat thrombotic disorders is warfarin, but as previously described it displays 
inconsistencies in dosing and response in patients requiring constant monitoring in order 
to maintain proper levels of the drug[48]. Other oral agents attack specific platelet targets 
like the ADP receptor (clopidogrel) or platelet cyclooxygenase (aspirin)[82-84]. The market 
for an oral anticoagulant remains unexploited at the present time, and the drugs in 
development, though promising, still display undesirable side effects. 
 Since our compounds are peptides, there are major challenges that must be 
overcome in order to design a molecule that will be both active and orally bioavailable. 
The most prominent problems hindering oral peptide therapeutics is the extreme 
sensitivity to serum proteases (peptides are readily degraded before having an 
opportunity to reach their target), and the often large size of the molecules, which limits 
absorption via passive diffusion[85, 86]. The stability and longevity of peptides can be 
improved by introduction of unnatural amino acid residues or modifications to the 
backbone structure, and the bioavailability may be improved by the development of 
peptide delivery systems[85, 87, 88].  
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 New peptide therapies are currently being developed for a variety of conditions 
including metabolic and immune disorders, neurological conditions, cardiovascular 
disease, HIV, and cancer[89]. A major success story is the design of Humalog, the first 
biosynthetic hormone optimized by DNA technology for the treatment of diabetes, which 
has developed into a blockbuster drug for Eli Lilly[90].  There are also several peptides in 
late-stage clinical trials including enfuvirtide (Fuzeon), a viral fusion inhibitor that blocks 
the virus before it enters CD4 cells[91]. The prospective for new peptide therapeutics has 
not reached its full potential, as there are still some hurdles to be overcome in both 
delivery and stability, but the success of the current peptide drugs does illustrate the 
possible future of these agents.  
This dissertation demonstrates that unnatural modifications can make an impact 
not only on the potency of the peptides, but can also influence the stability and 
bioavailability of these molecules. A variety of substitutions to the naturally occurring 
pentapeptide (RPPGF) have been explored and a mechanism of action for the new lead 
compound has been elucidated.  
 
RESEARCH OBJECTIVE. By utilizing an indirect approach to inhibit the hemostatic 
system, it is possible to modulate thrombus formation by targeting a family of receptors 
at the surface of platelets known as protease-activated receptors (PARs) that are activated 
by proteolytic cleavage by thrombin. The initial hypothesis for this research effort 
focused on interfering with the interaction between thrombin and the PARs. To 
accomplish this, analogs were designed to bind to the extracellular domain of the PARs 
thereby making it difficult for thrombin to dock to and cleave the receptor. The 
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consequent selective inhibition of the intramolecular activation step of the protease-
activated receptor should result in moderation of platelet activation and aggregation 
without interfering with the enzymatic activity of thrombin in the coagulation process. 
This selective inhibition would be expected to result in fewer side effects since thrombin 
could continue to function in the coagulation system. 
The thrombin inhibitory domain of bradykinin, the pentapeptide RPPGF, was 
exploited as a possible template for the peptides presented in this report. However, the 
inhibitory concentration of RPPGF is too high (Ki = 1.7 mM) and further substitutions to 
the sequence must be considered in order to achieve inhibition at a concentration low 
enough to warrant its consideration as a drug for the management of acute coronary 
syndrome. Chapter II describes the design and synthesis of a library of peptides with 
modifications at positions 4 and 5 leading to the discovery of a novel analog that is 42-
fold more potent than RPPGF against thrombin-induced platelet aggregation.  
The structure activity relationship study presented in Chapter II accomplished the 
first aim of the project, which was to produce a more potent analog of RPPGF. However, 
in the final portion of Chapter II, the issue of selectivity between direct thrombin 
inhibition and activity against platelet aggregation through the protease-activated 
receptors is raised. The lead peptide is more potent, but there is no selectivity as shown in 
the clotting assay results (measures the effect of molecules on the intrinsic and extrinsic 
pathways of the coagulation system). The mechanism of action of our analogs was thus 
explored in order to determine which mechanism is prominent in modulating the 
inhibition of platelet aggregation. Chapter III illustrates the many techniques employed to 
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determine whether the most potent peptides in our library are acting by inhibiting 
thrombin or through binding to PAR1 and PAR4. 
Finally, with Chapter IV we attempt to address the long-term goal of our project, 
which is to develop an orally available anticoagulant agent. Since the lead compound 
from the structure-activity relationship studies in Chapter II was found to be 12.7% orally 
bioavailable in rats, a new series of peptides was designed and synthesized to improve the 
pharmacokinetic profile. By assuming initially that the lead peptide is being absorbed 
through passive diffusion in the gastrointestinal tract, modifications were introduced to 
increase the lipophilicity and decrease the net charge of the peptides. The substituents 
selected were small and lipophilic (methyl and ethyl moieties) since the aim was to 
maintain the size and potency of the lead compound. From this final series, a new lead 
analog was discovered that is 3-fold more potent than the previous lead described in 
Chapters II and III. This compound is very promising since it represents a 135-fold 
improvement over RPPGF, and it possesses all unnatural amino acid residues along with 
other synthetic modifications, which are believed to contribute to its stability and oral 
bioavailability. 
In summary, this thesis presents a promising and novel class of anticoagulants 
with improved activity as well as stability and oral absorption. By synthesizing a peptide 
consisting of unnatural amino acid residues, we have developed a candidate that is 
currently patented and under FDA evaluation for an Investigative New Drug (IND) 
application and Phase I clinical trial for a single intravenous infusion for the treatment of 






STRUCTURE ACTIVITY RELATIONSHIP STUDIES  
TO OPTIMIZE RESIDUES AT POSITION 4 AND 5 
 
Previous work employing a combinatorial approach and rational drug design based on the 
RPPGF bradykinin fragment indicated that the change of configuration of arginine to D-
arginine and replacement of Pro2 by Oic (octahydroindole-2-carboxylic acid), known to 
improve potency of bradykinin antagonists, while maintaining proline in the third 
position of the sequence, led to pronounced improvements in potency, and resulted in the 
lead compound, D-Arg-Oic-Pro-Gly-Phe-NH2 (TH146)[92-94]. The analogs of TH146 
discussed throughout this dissertation were synthesized as linear sequences with an amide 
group at the C-terminus. Both features were determined to be essential for activity against 
platelet aggregation. A small series of peptides attempting to constrict the structure of 
TH146 through the cyclization of the linear peptide (compounds 59 thru 64) was 
developed early on in the project. All of the cyclic compounds were inactive in the 
functional assay indicating that maintaining the flexibility of TH146 was necessary for 
activity (this feature will be discussed further in Chapter III).  
With the above features delineated, the natural next step to further develop 
RPPGF analogs with increased potency for inhibition of thrombin-induced platelet 
aggregation was to substitute residues at positions 4 and 5. The current effort aims to 
optimize these remaining positions of TH146 by preparing analogs with substitutions at 
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Xxx4 and Xxx5. The results of these substitutions are summarized in Tables 1 and 2, 
where data are reported as the minimal concentration of the inhibitor necessary to 
completely block threshold γ−thrombin-induced platelet aggregation (IC100)[80, 81, 92]. 
Several previously synthesized and reported compounds are also included for 
comparison. A summary of the platelet aggregation data for all the compounds tested 
throughout this dissertation can be found in Appendix F.  
 
SAR STUDIES. Table 1 presents data for compounds with replacements for Gly at 
position 4 of D-Arg-Oic-Pro-Gly-Phe-NH2 (TH146). Since glycine can assume 
conformations allowed for L- and D-amino acids, alanine, the most conservative 
substitution for glycine, was examined in both L- and D- configurations (compounds 1 
and 2, respectively). As seen in Table 1, the D-Ala4 containing analog, compound 2, 
which showed 100% inhibition of platelet aggregation at 56 µM, is 10-fold more potent 
than compound 1 and 2.5-fold more potent than TH146 in γ-thrombin induced platelet 
aggregation assay.   
The successful results observed for peptide 2, encouraged us to explore further D-
amino acid substitutions in position 4. Among the remaining D-amino acid substituted 
analogs, compound 3, D-Arg-Oic-Pro-D-Asn-Phe-NH2 showed a modest improvement 
over TH146 with 100% inhibition of platelet aggregation at 83 µM, slightly less potent 
than 2. The remaining analogs in this series had comparable activity independent of the 
chemical nature of the residue’s side chain. Consequently, the trend observed in these 
peptides was that the requirement for residue 4 seemed to be primarily related to the 
configuration of the amino acid residue, rather than the actual side chain size and charge. 
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A possible explanation is that the D-stereochemistry moves the side chain “out of the 
way” while helping to orient the rest of the molecule. This assumption would be 
consistent with the improved activity displayed by 2, with the small alanine side chain. 
  
TABLE 1 
Position 4 modifications of TH146 
 
Compounds Sequence Inhibition of Threshold 
Platelet Aggregation 
  µM ± S.E.M 
RPPGF# Arg-Pro-Pro-Gly-Phe 680 ± 280 
TH146 D-Arg-Oic-Pro-Gly-Phe-NH2 140 ± 20 
1* D-Arg-Oic-Pro-Ala-Phe-NH2 550 ± 166 
2* D-Arg-Oic-Pro-D-Ala-Phe-NH2 56 ± 16 
3* D-Arg-Oic-Pro-D-Asn-Phe-NH2 83 ± 17 
4* D-Arg-Oic-Pro-D-Lys-Phe-NH2 133 ± 33 
5* D-Arg-Oic-Pro-D-Phe-Phe-NH2 133 ± 33 
6* D-Arg-Oic-Pro-D-Pro-Phe-NH2 167 ± 33 
7* D-Arg-Oic-Pro-D-Leu-Phe-NH2 300 ± 100 
9* D-Arg-Oic-Pro-D-Asp-Phe-NH2 567 ± 233 
10 D-Arg-Oic-Pro-D-Gln-Phe-NH2 400 ± 100 
11 D-Arg-Oic-Pro-D-Abu-Phe-NH2 275 ± 75 
12 D-Arg-Oic-Pro-D-Orn-Phe-NH2 250 ± 87 
13 D-Arg-Oic-Pro-D-Nle-Phe-NH2 275 ± 75 
Data presented are the mean ± S.E.M. of n > 3 independent experiments. The values given represent the 
minimal concentration of peptide necessary to inhibit 100 % of threshold γ−thrombin-induced platelet 
aggregation (IC100). # From Hasan et al.[80]. * Detones compounds synthesized by Kate Kojiro and Ping He. 
 
 
In parallel with the examination of varying Xxx4, we also introduced several 
substitutions at Xxx5 of the lead compound TH146. The data for the D-Arg-Oic-Pro-Gly-
Xxx5-NH2 series are presented in Table 2. It can be clearly seen that L-amino acids are 
preferred over D-amino acids in this series. This trend is exemplified by the sharp 
decrease in activity of compound 18, with D-phenylalanine at position 5 (IC100 = 833 
µM), in comparison to TH146 (IC100 = 140 µM). In addition, it appears that a larger 
aromatic side chain is preferred while aliphatic and polar groups are not well tolerated 
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(compounds 15, 16, 20, and 22 were all inactive in the functional assay). The most potent 
compound in this series, compound 14, replaces Phe5 with 2-Nal5 (3-(2-naphthyl)-L-
alanine) in D-Arg-Oic-Pro-Gly-Xxx5-NH2 resulting in a 3-fold improvement in activity 




Position 5 modifications of TH146 
 
Compounds Sequence Inhibition of Threshold 
Platelet Aggregation 
  µM ± S.E.M 
RPPGF# Arg-Pro-Pro-Gly-Phe 680 ± 280 
TH146 D-Arg-Oic-Pro-Gly-Phe-NH2 140 ± 20 
14* D-Arg-Oic-Pro-Gly-2-Nal-NH2 50 ± 0 
15* D-Arg-Oic-Pro-Gly-Glu-NH2 NE 
16* D-Arg-Oic-Pro-Gly-Nle-NH2 NE 
17 D-Arg-Oic-Pro-Gly-Phe(p-F)-NH2 200 ± 0 
18* D-Arg-Oic-Pro-Gly-D-Phe-NH2 833 ± 144 
19* D-Arg-Oic-Pro-Gly-Trp-NH2 350 ± 87 
20* D-Arg-Oic-Pro-Gly-His-NH2 NE 
21* D-Arg-Oic-Pro-Gly-1-Nal-NH2 200 ± 0 
22 D-Arg-Oic-Pro-Gly-Arg-NH2 NE 
23 D-Arg-Oic-Pro-Gly-Tyr-NH2 300 ± 100 
Data presented are the mean ± S.E.M. of n > 3 independent experiments. The values given represent the 
minimal concentration of peptide necessary to inhibit 100 % of threshold γ -thrombin-induced platelet 
aggregation (IC100). NE represents no effect or ≥ 1000 µM activity. # From Hasan et al.[80]. * Denotes 
compounds synthesized by Kate Kojiro, John Omnaas, and Ping He. 
 
 
Interestingly, there is a 4-fold decrease in activity when 1-Nal is substituted at 
position 5 as relative to 2-Nal5. A possible explanation for the difference in potency 
generated by these two close analogs is that the position at which the bulky naphthyl 
moiety is attached to the backbone influences the direction of the second ring of the side 
chain. In Appendix D, the 2-D representation of 1-Nal and 2-Nal are shown to describe 
the slight but yet important distinction between the positioning of the secondary ring of 
the aromatic system. This observation will become key in designing future series of 
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analogs with substituted phenylalanine residues that will be discussed in more detail later 
in this chapter and in Chapter IV. 
The substitution of Phe5 with 2-Nal in compound 14 encouraged the synthesis of a 
series of analogs with 2-Nal in position 5, re-examining several D-amino acid 
replacements in position 4, in order to assess whether the potency would be affected by 
this substitution. The results for this series of compounds are summarized in Table 3. 
Compound 57 [D-Arg-Oic-Pro-D-Gln-2-Nal-NH2] (IC100 = 83 µM) showed almost a 5-
fold increase in activity over compound 10 [D-Arg-Oic-Pro-D-Gln-Phe-NH2] (IC100 = 
400 µM). The remaining compounds, including the best compounds from the Phe series, 
showed only a slight improvement in activity when 2-Nal was positioned as the fifth 




Position 4 analogs of [2-Nal5]TH146 
 
Compounds Sequence Inhibition of Threshold 
Platelet Aggregation 
  µM ± S.E.M 
RPPGF# Arg-Pro-Pro-Gly-Phe 680 ± 280 
TH146 D-Arg-Oic-Pro-Gly-Phe-NH2 140 ± 20 
14* D-Arg-Oic-Pro-Gly-2-Nal-NH2 50 ± 0 
25 D-Arg-Oic-Pro-D-Ala-2-Nal-NH2 100 ± 35 
52 D-Arg-Oic-Pro-D-Phe-2-Nal-NH2 83 ± 17 
53 D-Arg-Oic-Pro-D-Ser-2-Nal-NH2 56 ± 16 
54 D-Arg-Oic-Pro-D-Thr-2-Nal-NH2 75 ± 14 
55 D-Arg-Oic-Pro-D-His-2-Nal-NH2 75 ± 25 
56 D-Arg-Oic-Pro-β-Ala-2-Nal-NH2 675 ± 197 
57 D-Arg-Oic-Pro-D-Gln-2-Nal-NH2 83 ± 17 
Data presented are the mean ± S.E.M. of n > 3 independent experiments. The values given represent the 
minimal concentration of peptide necessary to inhibit 100 % of threshold γ−thrombin-induced platelet 
aggregation (IC100). # From Hasan et al.[80]. * Denotes compound synthesized by Ping He. 
 
 
Following the results from our three initial series, we attempted to combine the 
best substitutions observed in the singly modified Xxx4 and Xxx5 series, but 
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unfortunately the effects do not appear to be additive. On the contrary, as shown in Table 
3, the projected best analog, compound 25 is only slightly more potent than TH146 (IC100 
= 100 µM). The explanation for the observed result may be related to the imposed steric 
and conformational changes with a less flexible backbone (due to D-alanine at position 4) 
and the bulky side chain of 2-Nal. The substitutions made at position 4 continued to 
display little influence on potency. 
Thus, we chose to examine other possible aromatic replacements for 2-Nal at 
position 5. As shown in Table 4, we introduced several variations of Phe that, like the 
successful 2-Nal5 substitution, were larger, aromatic, and lipophilic. In the initial analogs 
of the D-Arg-Oic-Pro-D-Ala-Xxx5-NH2 series, we chose to use Phe derivatives as a 
means of probing the requirements for interaction with the target receptor. Phe is present 
in the original lead compound, RPPGF, and, as seen in Table 2, the aromatic nature of 
Phe5 appears to be essential for inhibition of platelet activation. In addition, the 
substitutions were made at the para position of the aromatic ring since that would be 
representative of the 9th position of the 2-naphthyl aromatic system allowing for the 
further examination of the spatial requirements for this residue. As a first set of 
modifications, we chose to use small (methyl), intermediate (chloro), and large (phenyl) 

















Position 5 analogs of [D-Ala4]TH146 
 
Compounds Sequence Inhibition of Threshold 
Platelet Aggregation 
  µM ± S.E.M 
RPPGF# Arg-Pro-Pro-Gly-Phe 680 ± 280 
TH146 D-Arg-Oic-Pro-Gly-Phe-NH2 140 ± 20 
2* D-Arg-Oic-Pro-D-Ala-Phe-NH2 56 ± 16 
26 D-Arg-Oic-Pro-D-Ala-Bip-NH2 200 ± 100 
27 (FM19) D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2 16 ± 4 
28 D-Arg-Oic-Pro-D-Ala-Phe(p-Cl)-NH2 44 ± 11 
Data presented are the mean ± S.E.M. of n > 3 independent experiments. The values given represent the 
minimal concentration of peptide necessary to inhibit 100 % of threshold γ -thrombin-induced platelet 
aggregation (IC100). # From Hasan et al.[80]. * Denotes compound synthesized by Kate Kojiro. 
 
 
Within this initial small sample of synthesized analogs, there was a clear 
preference for the smaller substituent at the para position of Phe. This finding is not too 
surprising since analog 14 (2-Nal5) showed slight improved potency relative to TH146, 
but the size of the secondary ring created a possible problem. Compound 27 containing 
the p-methylphenylalanine, whose structure is shown in Figure 8, was 3.5-fold more 
potent than compound 2, 42-fold more potent than RPPGF, and had a 7-fold increase in 
potency compared to TH146 in γ-thrombin induced platelet aggregation. The structure 










Figure 8: The chemical structure of compound 27. 
 
 
 Following the discovery of analog 27, a new site for modification was introduced 
that provided for an extension of the D-Arg-Oic-Pro-D-Ala-Xxx5-NH2 series. Peptides 
were designed in which a variety of Phe derivatives with a wide range of chemical 
structure and position of the ring substitution was examined. A small series of analogs 
that possessed the p-methylphenylalanine at the fifth position with modifications at the 
fourth position with residues that had shown activity in previous series (D-Arg-Oic-Pro-
D-Xxx4-Phe(p-Me)-NH2) was also created. Table 5 summarizes the results observed for 
these compounds. From these extended series, three new potential lead compounds, 29 
[D-Arg-Oic-Pro-D-Ser-Phe(p-Me)-NH2], 33 [D-Arg-Oic-Pro-D-Ala-Phe(p-Br)-NH2], 
and 36 [D-Arg-Oic-Pro-D-Ala-Phe(p-I)-NH2] were identified. All three compounds 
shared similar potency in the thrombin-induced platelet aggregation assay, which is used 










Modifications at positions 4 and 5 in comparison to compound 27 
 
Compounds Sequence Fold Decrease in the 
Inhibition of Platelet 
Aggregation Potency vs. 27
27 (FM19) D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2 1*  
24 D-Arg-Oic-Pro-Gly-Phe(p-Me)-NH2 7 
28 D-Arg-Oic-Pro-D-Ala-Phe(p-Cl)-NH2 2.75 
29 D-Arg-Oic-Pro-D-Ser-Phe(p-Me)-NH2 0.81 
30 D-Arg-Oic-Pro-D-Asn-Phe(p-Me)-NH2 4 
31 D-Arg-Oic-Pro-D-Ala-Hfe-NH2 8 
32 D-Arg-Oic-Pro-D-Ala-Phe(p-NH2)-NH2 8 
33 D-Arg-Oic-Pro-D-Ala-Phe(p-Br)-NH2 1.1 
34 D-Arg-Oic-Pro-D-Ala-Phe(p-tBu)-NH2 2 
35 D-Arg-Oic-Pro-D-Ala-Phe(p-CN)-NH2 2 
36 D-Arg-Oic-Pro-D-Ala-Phe(p-I)-NH2 1 
37 D-Arg-Oic-Pro-D-Ala-Phe(2-Me)-NH2 2 
38 D-Arg-Oic-Pro-D-Ala-Phe(3-Me)-NH2 4 
39 D-Arg-Oic-Pro-D-Ala-Phe(p-NO2)-NH2 3 
40 D-Arg-Oic-Pro-D-Ala-Phg-NH2 2 
41 D-Arg-Oic-Pro-D-Ala-Phe(p-COOH)-NH2 35 
The data represent the fold increase in concentration of the peptide necessary to inhibit threshold γ-
thrombin-induced platelet aggregation when compared to compound 27 (FM19) (*IC100 = 16±4 µM). The 
error for this study is in the range of 1-3 fold due to the variable nature of the platelet aggregation assay.  
 
 
Most of the modifications at the para postion of Phe5 were well tolerated as 
demonstrated by the 1-3 fold decrease in activity as compared to analog 27 for the 
majority of the peptides. However, a few substituents such as polar groups (compounds 
32 and 41) and the elongated aromatic side chain of homophenylalanine (Hfe) in 31 
produced much less potent analogs (8 fold and higher decrease in potency). The 
additional carbon bond in Hfe not only extends the side chain by one methylene group, 
but it also influences the position of the aromatic ring by introducing an extra rotational 
angle to the side chain. Both differences may explain the changes in activity for analog 
31. There is definite evidence that a small alkyl group (p-Me5) and halogens (p-Br5 and p-
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I5) are preferred at the fifth position and that D-serine can be exchanged for D-alanine at 
position 4. 
 
SELECTIVITY BETWEEN ANTI-PLATELET ACTIVATION AND CLOTTING 
ACTIVITY. The discovery of compound 27 and its equipotent analogs (29, 33, and 36) 
fulfilled our first goal of producing a more active analog of RPPGF and TH146. 
However, we were also interested in producing analogs with improved selectivity 
between inhibition of the clotting properties of thrombin and platelet aggregation 
mediated by the PAR family. In order to test for selectivity, the clinical anticoagulation 
tests (APTT, PT and TCT) were employed to measure the ability of our lead compound 
to interfere with the clotting cascade. The activated partial thromboplastin time (APTT) 
was used to assess the affect on the intrinsic pathway (from an internal injury) while the 
prothrombin time (PT) probed the extrinsic pathway (external injury)[16]. The third test, 
the thrombin clotting time (TCT), determined the inhibition of the final step of the 
coagulation system where thrombin cleaves fibrinogen to produce insoluble fibrin. The 
combination of these three tests allowed for the complete assessment of the extent to 
which our compound is inhibiting the clotting cascade.     
Like RPPGF and TH146, compound 27 also displays direct inhibition of thrombin 
as evident by the results of the clinical coagulation assays (APTT, PT and TCT). The 
clinical studies demonstrated that at 1.56 µM, 1.56 µM, or 0.78 µM of 27, there was a 
significant prolongation (p < 0.05) of the APTT, PT, or TCT, respectively. Compound 27 
is a 10-40 fold more potent inhibitor of thrombin clotting properties than is TH146, 
which was deemed a direct inhibitor of thrombin at higher concentrations than 27[92]. The 
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data displayed in Figure 9 indicate that the improved antiplatelet activity of compound 27 
may be partially linked to its direct interaction with thrombin. Consequently, this 
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Figure 9: Influence of 27 on coagulation assays. Normal human plasma was incubated with increasing 
concentration of 27 and the APTT (red bars), PT (purple bars), or TCT (yellow bars) was determined as 




In order to further explore the requirements for interaction with the receptor and 
the selectivity of their anti-coagulant activity, compound 27 and its analogs (29, 33, and 
36) were used in order to examine the mechanism of action of this class of compounds. In 
the subsequent chapter (Chapter III), we employed in vitro and in vivo assays to probe the 




BIOCHEMICAL CHARACTERIZATION OF LEAD ANALOGS AND 
ELUCIDATION OF THE MECHANISM OF ACTION 
 
IN VITRO CHARACTERIZATION OF ANALOGS. As described in Chapter II, our 
structure-activity relationship studies of TH146 led to four good candidates for further 
study, compounds 27, 29, 33, and 36. In the present chapter, we examine these lead 
analogs more extensively to assess their possible selectivity as thrombin induced PAR 
activation inhibitors. The previously described clinical anticoagulant assays (APTT, PT, 
and TCT) were used to assess the anti-clotting activity of the three new analogs along 
with 27 and, the results are summarized in Table 6.  
Similar activity as compound 27 was observed for compound 29 on the clotting 
time of normal human plasma using the APTT, PT, and TCT assays (3.13 µM, 1.56 µM, 
and 0.39 µM, respectively) suggesting that this analog is inhibiting both the extrinsic and 
intrinsic clotting pathways as well as directly interfering with fibrin formation. The 
remaining two analogs (compounds 33 and 36) were less potent inhibitors of the intrinsic 
and extrinsic pathways (4-16 fold less potent), but displayed activity in the thrombin 
clotting time assay comparable to compound 27 (0.78 µM). The data indicate that even 
though all four analogs have a significant inhibitory effect against α-thrombin, the 
modifications seem to have different effects on how each compound modulates the 
clotting cascade. This suggests that analogs 33 and 36 are inhibiting fibrin formation 
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(TCT assay), but are not interfering with the upstream mechanisms. On the other hand, 
27 and 29 are able to inhibit not only the final step of the clotting cascade, but are also 
inhibiting the pathways leading to thrombin formation (from prothrombin as described in 
Chapter I). The interaction of all four compounds with other clotting factors involved in 
the intrinsic and extrinsic pathways was tested, and the data is presented later in this 
chapter.      
TABLE 6 
 
Influence of peptide analogs on coagulation assays. 
 
Compounds Sequence Minimal Concentration for 
Prolongation  (p < 0.05) 
  APTT PT TCT 
  µM 
27 D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2 1.56 1.56 0.78 
29 D-Arg-Oic-Pro-D-Ser-Phe(p-Me)-NH2 3.13 1.56 0.39 
33 D-Arg-Oic-Pro-D-Ala-Phe(p-Br)-NH2 12.5 6.25 0.78 
36 D-Arg-Oic-Pro-D-Ala-Phe(p-I)-NH2 25 6.25 0.78 
Normal human plasma was incubated with increasing concentration of 27 and the APTT, PT, or TCT was 
determined as described under Materials and Methods. The data represent the mean ± standard deviation of 
at least three independent experiments. 
 
 
 Since RPPGF and TH146 were shown to interact with the active site of thrombin, 
the peptide analogs’ ability to inhibit α-thrombin cleavage of a substrate was measured. 
The assay used Sar-Pro-Arg-p-nitroaniline as the substrate in the presence of a pre-
determined threshold concentration of α-thrombin (2 nM) necessary for detectable 
cleavage[92]. This assay works by measuring the change in absorbance due to the presence 
of free p-nitroaniline as a product of thrombin cleavage of the substrate. All four analogs 
inhibited the enzymatic activity of both α-thrombin and γ-thrombin with Ki values 
ranging from 5.9-7.3 µM and 42-59.2 µM, respectively (Table 7). These data indicate 
that all four compounds are approximately 15-fold better inhibitors of thrombin cleavage 
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of substrates than is TH146 (Ki = 91.7 µM). To be certain that the analogs’ anticoagulant 
activity was due to their ability to inhibit thrombin, other enzymes in the coagulation 
system were tested with the corresponding chromogenic substrate (see Materials and 
Methods section). Factors Xa, XIa, and VIIa were selected since they are important 
enzymes in the coagulation cascade that lead to the activation of thrombin.  None of the 
four lead peptides inhibited the enzymatic activity of these clotting factors. Therefore, 




Effect of peptide analogs on enzymatic activity of thrombin and related coagulation enzymes. 
 
Compounds α-IIa γ-Iia FXa FXIa FVIIa FVIIa+TF
 Ki (µM ± S.D.) 
27 5.9 ± 1 54.35 ± 16 NI NI NI NI 
29 6.8 ± 0.9 42.23 ± 6 NI NI NI NI 
33 7.3 ± 2 48.72 ± 7 NI NI NI NI 
36 6.4 ± 1 59.24 ± 13 NI NI NI NI 
 The enzymatic activity assays were performed as described under Materials and Methods. The presented 
are mean ± standard deviation of three independent experiments. NI: no inhibition. 
 
  
 To further elucidate the mechanism of action of our peptides at the cellular level, 
the calcium mobilization assay was utilized to probe the effect of each analog on the 
downstream signaling of α-thrombin in normal human fibroblast cells[92]. During platelet 
activation, thrombin cleavage of PAR1 is known to induce calcium mobilization in cells 
through the intracellular action of Gq. Gq activates phospholipase Cβ54, triggering 
phosphoinositide hydrolysis resulting in calcium influx and activation of protein kinase 
C[31, 35, 96]. Therefore, by using a calcium ion indicator (Fura2), calcium mobilization can 
be monitored as a reporter of platelet activation[39, 97, 98]. First the threshold concentration 
of α-thrombin necessary to stimulate maximal calcium influx (2 nM α-thrombin) was 
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determined. Then a range of concentrations of each peptide was incubated with the cells 
prior to the addition of threshold α-thrombin. The results are displayed in Figure 10 as a 
plot of concentration of peptide versus percent calcium influx. 
 When 80 µM of either compound 27 or 29 was present, there was 97% inhibition 
of thrombin-induced calcium mobilization.  As the concentration of these peptides was 
decreased to 3 µM, there was a corresponding decrease in the inhibition of calcium 
mobilization to 69% and 59%, respectively.  At 0.38 µM compound 27 and 29, there was 
full recovery of α-thrombin-induced calcium mobilization. IC50 values for the inhibition 
of calcium influx for compounds 27 and 29 were 12 µM and 15 µM, respectively. 
Consistent with the results observed in the in vitro APTT, PT, and TCT assays, 
compounds 27 and 29 were more potent inhibitors of calcium mobilization in cells than 
 
α
were the other two analogs (compounds 33 and 36). 
Figure 10: The effect of peptides on -thrombin induced calcium mobilization. 
Data represents the influence of a range of concentra ions of 27 and 29 on threshold α-thrombin-induced 
calcium mob e performed 
Concentration (µM)




















ilization in normal human lung fibroblast cells. Calcium mobilization studies wer
as described under Materials and Methods. Values for each concentration of peptide were determined by 
calculating the area under the curve and are expressed as percentage of calcium influx. The data represent 
the mean ± standard deviation of three independent experiments. 
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 Previous work published by Hasan et al.[81] suggested that RPPGF inhibits PAR1 
proteolysis by both interacting with the active site of thrombin and by binding directly to 
the extracellular domain (approximately 71 amino acid residues of the N-terminus 
located outside of the cell) of the receptor. Thus far, our data suggest that the peptide 
analogs are clearly interacting with thrombin and inhibiting its enzymatic activity both in 
vitro and in cells, but are these peptides interacting with our target receptors, PAR1 and 
PAR4, at the surface of platelets? To answer this question, an experiment to measure 
whether compound 27 interferes with the binding of 15 µM RPPGFK-biotin to the 
exodomain of PAR1 was performed and the results are shown in Figure 11. Biotin was 
used as the labeling agent for these experiments, and its presence was detected by 
streptavidin horseradish peroxidase conjugate system.  
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Figure 11: Inhibition of RPPGFK-biotin binding to rPAR1EC by 27. The competition-binding assay was 
performed as described in Materials and Methods. The data are normalized to wells containing no inhibitor 
At 30 µM, 300 µM, and 1000 µM, compound 27 displaced 23%, 52%, and 69% 
of RPP
that represents 100% of binding and are represented as the mean ± standard deviation of at least three 
independent experiments. 1 mM TH146 was used as a positive control to ensure that the experiment 
worked properly.   
 
 
GFK-biotin, respectively (Figure 11).  The data indicate that 27 inhibited the 
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binding of 15 µM RPPGFK-biotin to the extracellular domain of PAR1 with an IC50 of 
275 µM. The results show that compound 27 is about 2-fold less potent than TH146 at 
inhibiting the binding of the labeled compound to PAR1 (IC50 = 160 µM for TH146)[92]. 
The same type of experiment was applied to PAR4 and at 30 µM, 300 µM, and 1000 µM, 
compound 27 behaved in a similar manner (IC50 = 300 µM). The results from the 
competition binding experiments are suggestive of the interaction with the receptor. 
However, when comparing the inhibition of the lead compound to TH146 it was observed 
that compound 27 is less potent at displacing RPPGFK-biotin as seen in the increased 
IC50 value[92]. In the physiological assay (platelet aggregation) peptide 27 is 7-fold more 
potent than TH146. So if the activity is achieved through binding to the receptor and 
consequent inhibition of platelet aggregation, a different outcome would be expected 
(lower IC50 value for 27 relative to TH146 since the latter is a weaker inhibitor of platelet 
aggregation).  
The results of the competition-binding assay compelled us to question the 
specificity and accuracy of the assay. In order to test if the binding was sequence specific, 
the next experiment involved synthesizing two compounds with the same amino acid 
composition as 27, but with different sequences (Phe(p-Me)-Oic-D-Arg-Pro-D-Ala-NH2 
and D-Ala-Pro-D-Arg-Oic-Phe(p-Me)-NH2). The results shown by Nieman et al.[92] 
indicated that the binding of TH146 to PAR1 and PAR4 exodomains was sequence-
dependent; however, when the “scrambled” analogs of 27 were tested, both were inactive 
in the platelet aggregation assay, but they competed with RPPGFK-biotin for binding to 
PAR1 and PAR4 with potencies comparable to 27. Consequently, other “scrambled 
peptides” were synthesized and the experimental conditions were optimized, but similar 
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results were observed. Thus, there was still a need to find a different way to observe 
whether our new lead compound was interacting with the exodomain of PAR1 and 
PAR4. 
 In order to resolve the issues encountered with the competition assay, we decided 
to biotinylate compound 27 (27K-biotin [D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-Lys(biotin)-
NH2]) as a means of directly assessing the binding of our lead compound to PAR1 and 
PAR4. Recombinant PAR1 exodomain (rPAR1EC) was prepared as described by Hasan et 
al.[81], and the binding protocol was used as previously described by Nieman et al.[92]. 
rPAR1EC was incubated overnight at 4°C in 0.1 M Na2CO3, pH 9.6, to link the receptor to 
the wells of a 96-well microtiter plate. After incubation, the wells were washed five times 
with 10 mM NaH2PO4, 150 mM NaCl, pH 7.4, and containing 0.05% Tween 20. The 
wells were then blocked with 0.2% bovine serum albumin in PBS with 0.05% Tween 20 
for one hour at 37°C. After blocking and washing of the wells, the bound rPAR1EC was 
incubated with various concentrations of 27K-biotin in the presence (non-specific 
binding) and absence (total binding) of 150-fold excess of unlabeled 27. The specific 
binding curve (green line) for 27K-biotin based on the time course of binding to PAR1 is 


























Figure 12: Compound 27K-biotin binding to rPAR1EC linked to microtiter plates. The binding assay was 
performed as described in Materials and Methods. The data are represented as the mean ± standard 
deviation of three independent experiments. 
 
 
The results of the direct binding studies demonstrate that compound 27 is 
specifically binding to the exodomain of PAR1 (green line in Figure 12). However, the 
results from this experiment was once again questioned when the competition-binding 
experiments were performed in the presence of negative controls such as “scrambled 
peptides” and D-Glu-Oic-Pro-D-Ala-Phe(p-Me)-NH2 (inactive compound due to the lack 
of positively charged D-arginine in position 1). The “scrambled peptides” were able to 
compete with 27K-biotin while D-Glu-Oic-Pro-D-Ala-Phe(p-Me)-NH2 was not. A 
possible explanation for the discrepancy in the data is that the binding experiments are 
not particularly representative of the environment necessary for compound 27 to interact 
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with the receptor at the cellular level. By linking the rPAR1EC to the wells in the presence 
of 0.1 M Na2CO3 buffer, a negatively charged surface is created that may be responsible 
for the binding of peptides due solely on the presence of the positively charged D-
arginine residue.  
In order to further investigate the mechanism of action of the lead compound, Dr. 
Schmaier’s laboratory is currently working on a cell-based assay using HeLa cells that 
were engineered to express PAR1 and PAR4 in order to assess the binding of compound 
27 to the receptors in a more natural setting. The receptors are expressed at the surface of 
the cells to mimic their expression in normal platelets. The 5-carboxyfluorescein labeled 
compound 27 (27K-FAM [D-Arg-Oic-Pro-D-Ala-Phe(pMe)-Lys(5-FAM)-NH2]) was 
synthesized in order to be used in flow cytometry studies to determine if the peptide is 
specifically binding to the receptors in cells. The labeled compound has maintained the 
characteristics of compound 27 as determined by the activity in the platelet aggregation 
assay (28 ± 6 µM). Therefore, the analog is a good candidate for probing the interaction 
of the peptide and PAR1 and PAR4 in cells.      
 
IN VIVO STUDIES WITH COMPOUND 27. The in depth in vitro experiments have 
provided insight into the mechanism of action of the peptide analogs, in particular 
compound 27. The data indicate that the lead compound is inhibiting platelet aggregation 
through the inhibition of thrombin both in vitro and in cells. The natural progression was 
to analyze the effects of the lead compound in vivo. The animal studies were performed 
by Mark Warnock in Dr. Schmaier’s lab. These studies were carried out to determine the 
pharmacokinetic profile of compound 27 as well as its ability to affect the coagulation 
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system in an animal model[92]. The data from the pharmacokinetic studies performed in 
dogs showed that compound 27 has a prolonged half life (t1/2α) of 32.6 ± 3.2 min and 
slower clearance of 8.1 ± 5.1 ml/min/kg when compared to TH146 (t1/2α = 3.1 ± 0.3 min 
and clearance of 66 ± 32 ml/min/kg), and the plasma half life of 27 is an order of 
magnitude longer than the natural peptide RPPGF[92]. The studies showed that compound 
27 prevents thrombosis in the mouse. Analog 27, at 0.4 mg/kg IP, produces a significant 
prolongation (p<0.005) in the time to occlusion of the mouse right carotid artery in the 
Rose Bengal model for arterial thrombosis[92].  
Following up on these promising initial results, our collaborator, Dr. John 
Hilfinger from Therapeutic Systems Research Laboratories, Inc., performed oral 
absorption and intestinal stability studies through the analysis of rat plasma and intestinal 
samples using LC/MS/MS. The data suggest that our lead compound is fairly stable, 
shows modest intestinal permeability, and demonstrates 12.7% oral bioavailability 
(Tables 8 and 9, and Figure 13). Investigations were performed on 27 to determine the 
stability in buffer, intestinal washings (also termed perfusates), and intestinal 
homogenates that were prepared from rat intestines. In these assays, aliquots of the 
synthetic peptide solution (1 mg/ml) were added to 0.9 ml of MES buffer, pH 6.5, 
intestinal perfusate, or intestinal homogenate at 37oC and sampled over a 90 minute time 
period and assayed by LC/MS/MS analysis. In simple MES buffer, at pH 6.5, the half life 
of the compounds in pH 6.5 buffer varied from approximately 2 hours to stable over the 
time frame tested.  As shown in Table 8, peptide 27 is 2-19 fold more stable than TH146, 
and peptide 29 showed no measurable breakdown throughout the duration of the assay.  
From these data, it is clear that those compounds with fewer natural peptide bonds were 
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the most stable in the intestinal setting, and are therefore more likely to be absorbed intact 
from the intestinal segment.   
TABLE 8 
 
Estimated half lives (t½) for selected Thrombostatin analogs in buffer (pH 6.5), 
intestinal homogenates, and intestinal perfusate 
 
Compounds MES Buffer 
(pH 6.5) 
Intestinal Perfusate Intestinal 
Homogenate 
t1/2  (min) 
TH146 178.70 110.55 40.32 
27 363.01 313.99 756.95 
29 stable stable ND 
Stable refers to no observed breakdown over the time course of the experiment. ND: not determined. 
 
 
Since compounds 27 and 29 displayed considerable stability in both buffer and in 
the intestinal setting, they are likely to be absorbed intact from the gastrointestinal tract. 
The in situ single pass perfusion experiments (data not shown) confirmed our assumption 
by showing that compound 27 displayed modest intestinal permeability, suggesting that 
this stable peptide could have the potential to be delivered orally. In order to test this 
hypothesis, the bioavailabilty of compounds 27 and 29 was determined by direct 
instillation of compounds into the duodenum, and the systemic levels of each peptide 
were monitored through blood collection. Figure 13 shows that substantial levels of both 
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  Figure 13: Systemic plasma levels of compound 27after direct instillation into duodenum. 3 mg of 
TH146, 27, or 29 were injected into the duodenum and blood was collected from the jugular vein at 0, 1, 2, 
3, and 4 hours. The plasma levels were determined using LC/MS/MS analysis. The insets contain Cp vs. 
time profiles after IV dosing of 27 (top) and 29 (bottom). The assay was performed as  
described in Materials and Methods.  
 
 
 In order to determine the oral bioavailability of the analogs, the area under the 
curve (AUC0-t) was calculated using the Cp (plasma concentration) versus time data 
(Figure 13). To derive the AUC directly from the Cp, a numerical approximation method 
known as trapezoidal rule was employed. In this technique the area under the curve is 
divided into segments assumed to be trapezoidal in shape then the sum of the segments 
gives an approximation for the definite integral[99, 100]. The calculated values for AUC0-t 
are displayed in Table 9 along with the octanol:water partition coefficient at pH 7, Log 
DpH7, used to determine the lipophilicity of the analogs. Since both analogs are 
significantly more lipophilic than TH146, we expected that they would display higher 
oral bioavailability. Compound 27 was 12.7% bioavailable, which was in accordance 
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with the lipohilicity data. However, analog 29 was not as successful (5.2%), which was 
surprising due to its stability, lipophilicity profile, and plasma concentration over time. 
The oral bioavailability results for 29 are currently being re-evaluated by our collaborator 
along with compounds 33 and 36 to elaborate on the features required for improved 




Compounds 27 and 29 show increased systemic exposure compared to TH146 
 




TH146 D-Arg-Oic-Pro-Gly-Phe-NH2 0.016 0.21 ± 0.01
27 D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2 1.208 (12.7%) 0.52 ± 0.02
29 D-Arg-Oic-Pro-D-Ser-Phe(p-Me)-NH2 3.933 (5.2%) 0.52 ± 0.01
The AUC for the analogs was determined from the Cp x time data in Figure 13 using the trapezoidal rule.   
Oral bioavailability for the compounds (in parenthesis) were calculated from the ratio of the oral AUC 
divided by the compounds IV AUC data and a factor to account for the differences in the oral and IV dose 
(3 mg oral vs 0.2 mg IV). The Log DpH 7 value for TH146, 27 and 29 are presented in the final column. 
 
 
Compound 27 thus shows promise as a potent, orally available compound, and a 
patent has been applied for and accepted for this group of analogs as a new class of 
anticoagulant compounds (U.S. Patent Application #20060276402). In addition, as 
preparation for an Investigative New Drug application (IND), compound 27 underwent 
toxicology studies at independent research facilities to determine its safety profile. 
Toxicology studies on rats and dogs were performed to establish the therapeutic window 
for 27. These experiments determined that the concentration of agent necessary to 
prevent arterial thrombosis in vivo was over an order of magnitude higher than the no-
observable-adverse-effect-level (NOAEL) indicating that the compound has an 
acceptable therapeutic window. In addition, genotoxicity assays were performed and 
compound 27 was negative for mutagenic activity in selected bacteria, for induction of 
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structural or numerical chromosome aberrations in human lymphocytes, and for mouse 
bone marrow micronucleus frequency. In summary, the data collected indicate that 27 is 
well positioned for submission of its IND to the FDA for use in a human Phase I clinical 
trial to measure its pharmacokinetics and pharmacodynamics with a single intravenous 
infusion for the treatment of myocardial infarction and high-risk active angina. 
 
CRYSTAL STRUCTURE SUPPPORTS THE BIOLOGICAL DATA. The biological 
data gathered thus far suggest that our lead compound acts as an antiplatelet and 
anticoagulant agent through the interaction with the active site of thrombin. This is 
contrary to our original hypothesis in which we sought to design a compound that would 
interact with the extracellular domain of PAR1. However, we were aware that bradykinin 
and RPPGF also interacted with the active site of thrombin at high concentrations (Ki = 
1.7 mM)[81]. Through our design efforts we have made a low micromolar inhibitor of 
thrombin (Ki = 6.2 µM). Dr. Enrico Di Cera from Washington University recently 
elucidated the crystal structure of compound 27 bound to the active site of thrombin 
(Figure 14 represents the unpublished structure). This structure provides the definitive 
confirmation that our lead compound is indeed interacting with thrombin.  
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Figure 14: Crystal structure of 27 bound to the active site of thrombin. 
Katrina Lexa created the image with the peptide in blue and thrombin in gray. 
 
 
The design of a direct thrombin inhibitor was not the original goal of our research 
efforts, but there is great potential in developing an agent that displays favorable stability 
and oral bioavailability with minimal toxicological effects as eluded to in Chapter I. With 
the crystal structure in hand we were able to study the interaction of our compound with 
thrombin and determine the class of compounds that would best classify compound 27. 
Katrina Lexa, a rotation student in the Mosberg lab, was able to overlay the structure of 
27 bound to thrombin with other crystal structures of direct thrombin inhibitors available 
in the Protein Data Bank. Figure 15 displays the resulting overlay and shows that our 
compound has the distinct features of hirudin-like analogs with the sequence D-Phe-Pro-
Arg. However, 27 acts as a retrobinder at the active site of the enzyme since its N-
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terminus fits into the S1 pocket and the main chain runs parallel in respect to the Ser141-
Gly216 of the active site, hence the D-Arg-Oic-Pro-D-Ala-Phe(pMe)-NH2 sequence[81, 101, 
102]. In normal substrate binding to thrombin, the backbone of the peptide spans from C-
terminus to N-terminus. The D-Arg1 of 27 occupies the S1 pocket that corresponds to the 
C-terminus arginine of the hirudin-like inhibitors. The guanidino moiety is in prefect 
alignment with the carboxyl group of Asp189 of the active site. The presence of Oic at 
position 2 followed by Pro3 creates a sterically restricted backbone that forces the p-
methylphenylalanine side chain to be in close proximity with Trp215, another important 
site of interaction in the active site. This location is consistent with the position of the N-
teminus D-Phe residue of the hirudin analogs.     
 
Figure 15: Overlay of compound 27 (in blue) with other direct thrombin inhibitors bound to the active site 
of the enzyme. The inhibitors used in the overlay are hirudin (3HAT-teal), hirugen (1AIX-orange, 1B5G-
aqua, 1A5G-red, 1A46-yellow), hirugen residues 54-65 of hirudin (1BCU-green), hirulog (1ABI-dark 
green), thiazole containing hirugen (1TBZ-cyan), and D-Phe-Pro-Arg-chloromethylketone (1ABJ-lavender, 
1B7X-magenta, and 1HAI-purple).   
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 The next step in understanding the interaction of the lead peptide with thrombin 
was to look at the structure activity relationship data and apply it to the computational 
model. Our approach was to simply model the binding of our analogs by homology to the 
structure of compound 27 bound to thrombin. This approach ignores the possible 
conformational differences in the analogs so it is only a crude representation of the 
possible interactions with the active site residues. Numerous substitutions have been 
made at positions 4 and 5 of the peptide, and the resulting effect on activity was 
described in detail in Chapter II. Katrina Lexa has developed a computational model for 
several analogs of 27 based on its structure and position of the lead compound in the 
crystal structure, as shown in Figure 16. 
The analogs selected have varying activities and were placed in the active site of 
thrombin as shown in Figure 16. This approach will allow us to generate structures for 
new analogs with improved activity and more favorable pharmacokinetic characteristics. 
Figure 16 illustrates the differences in position 5 substituents as compared to compound 
27. When the correlation between the platelet aggregation data and the computational 
studies was drawn, it suggested that the modifications leading to a change in positioning 
of the phenylalanine side chain translated into a change in activity. The compounds 
selected for analysis were compounds 40 (D-Arg-Oic-Pro-D-Ala-Phg-NH2), 31 (D-Arg-
Oic-Pro-D-Ala-Hfe-NH2), 44 (D-Arg-Oic-Pro-D-Ala-D-Phe(2,4-DiMe)-NH2) and the 






Figure 16: Overlay of structure activity relationship using the
to active site of thrombin for docking the peptides. 27
40 in green, 44 in orange and 31 in m
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directly to the alpha carbon. In 
t the para position on the ring. 
he functional assay as shown in 
ivity could be explained by the 
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r, this particular analog was 
analysized here since it fits into the trend we observed for the possible importance of the 
relative position of the aromatic ring of the fifth residue to Trp215.    
 The spatial differences are even more accentuated in compound 31 (magenta) 
with homophenylalanine (Hfe) at the fifth position. The unusual residue possesses an 
additional methylene between the alpha carbon and the aromatic ring. In this case, the 
addition of the alkyl moiety changes not only the distance, but also the orientation of the 
ring due to the torsion angle introduced by the additional carbon-carbon bond. As 
illustrated in Figure 16, the aromatic ring faces away from the Trp215 residue, perhaps 
accounting for the 8-fold decrease in activity in the platelet aggregation assay. When 
observing the final compound, 44 (orange), docked to the active site, the D-
stereochemistry of the amino acid residue (D-Phe(2,4-DiMe)5) appears to position the 
ring somewhere between Phg and Hfe. Since the potency of 44 is 6-fold lower than that 
of 27 (in between 2 and 8 fold), this is consistent with the binding interaction trend 
between the Trp215 side chain and the fifth residue side chain of the inhibitor.  
We can thus conclude that the orientation of the residues at position 5 plays a role 
in the activity of the analogs suggesting that the interaction between the residue and 
Trp215 is important for activity. The ability to correlate the functional activity with the 
docking studies solidifies the potential of employing the computational model for future 
development of novel analogs with optimized interactions with the important residues of 
the active site of thrombin. More extensive analysis of the docking results are ongoing in 




SYNTHESIS OF LIPOPHILIC ANALOGS OF COMPOUND 27 WITH 
IMPROVED STABILITY AND ORAL BIOAVAILABILITY. 
 
As previously stated in Chapter I, the long-term objective of the project is to develop an 
orally bioavailable drug for treatment of individuals with acute coronary syndromes. 
Suitable progress has been made towards designing an inhibitor with favorable 
pharmacokinetic characteristics as shown in Chapter III with the results from the 
intestinal stability and absorption studies carried out by our collaborator, Dr. John 
Hilfinger (TSRL, Inc.). Since our lead compound is composed of unnatural amino acid 
residues, it is relatively stable in the intestinal setting and is more likely to be absorbed 
intact from the intestinal segment than are unmodified peptides. Many of the agents 
routinely used for anticoagulant and/or antiplatelet activity, such as heparin, are 
administered intravenously. Other oral agents attack specific platelet targets like the ADP 
receptor (clopidogrel) or platelet cyclooxygenase (aspirin).  
Compound 27, which displays modest oral bioavailability with 12.7% availability 
after simulated oral dosing as measured by LC/MS/MS, represents an excellent lead for 
the development of orally available thrombin inhibitors. Our aim is to improve the oral 
bioavailability of peptide 27 by incorporating other chemical modifications in order to 
make the compound less charged and more lipophilic. There are several sites on our lead 
pentapeptide that could be modified including both the N- and C-termini, the guanidino 
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moiety of the D-arginine in position 1, and the aromatic ring in position 5. For instance, 
di-substituted phenyalanine would increase the lipophilicity of the analog and acetylation 
of the N-terminus would decrease the net charge of the peptide. The targeted sites on the 
lead compound that could be modified are depicted in Figure 17. 
 
Figure 17: Structure of 27 with the sites of modification marked with red rectangles. 
 
 
The first modifications involved reducing the positive charge of the peptide by 
acetylating the N-terminus in one analog (58) and replacing the D-Arg with D-citrulline 
(guanidino group is substituted by a carbamoyl group) in another (this peptide was 
synthesized by Anjanette Turbiak). Both analogs were inactive in the platelet aggregation 
assay indicating that these are key features necessary for activity. Consequently, we 
decided to decrease the polarity of the guanidino group at position 1 by synthesizing Nω-
methyl-D-arginine (1b in Scheme 1) and incorporating the residue into the peptide[103-
105]. The synthesis of protected Nα-Z,Nω-(Me, Mtr)-D-arginine (1) for incorporation into 




Scheme 1: Synthesis of Nω-alkyl-D-arginine residues. 
a: acetone, reflux; b: copper (II) acetate, 1:1 ammonium and water. 
 
Scheme 2: Protection of N-te inus and side chain group. 





















































































In parallel with the position 1 modifications, di-substituted phenylalanine analogs 
were synthesized and incorporated into the fifth position of the pentapeptide. These 
analogs have an additional methyl group at either ortho or meta positions on the aromatic 
ring. The synthesis of the di-substituted phenylalanine analogs is displayed in Scheme 
3[108]. The position 5 analogs were designed to serve two purposes: increase the 
lipophilicity due to the additional alkyl group and potentially enhance the activity since 































Scheme 3: Synthesis of Fmoc-3,4-dimethylphenylalanine. 
a: sodium in absolute alcohol saturated with N2,, reflux; b: 6 N HCl, reflux under N2; c: Fmoc-
OSu in DMF, acetone and 10% sodium bicarbonate, vigorous stirring, room temperature. Synthesis of 2,4-
dimethylphenylalanine followed the same protocol starting with 2,4-dimethylbenzyl chloride.   
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The final site selected for modification was the amide group at the C-terminus of 
compound 27. Unlike the N-terminus, the C-terminus of our lead peptide could be 
extended as was shown with the synthesis of labeled peptides, which required the 
addition of a C-terminal lysine residue in order to link the labeling agent. The labeled 
analogs were just as active as the unlabeled peptide in the platelet aggregation assay (19-
28 µM). Two analogs were synthesized that contained N-alkyl modifications, compound 
43 (N-methyl) and compound 48 (N-ethyl). These analogs were synthesized through the 
use of alkylated indole resins that give N-alkylated amides after cleavage with TFA 





































Scheme 4: Synthesis of N-methyl substituted carboxamide using [3-({methyl-Fmoc-amino}-
methyl)-indol-1-yl] acetyl AM resin. 
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The proposed peptide analogs are displayed in Table 10 along with the 
corresponding results from the platelet aggregation assay. For clarification, compounds 
44/45 and 46/47 were synthesized as a mixture of diasteriomeric peptides due to the use 
of racemic amino acid residues as starting materials (4b in Scheme 3). The diasteriomers 
were separated by RP-HPLC and the tentative assignment of 45 and 47 as L-





Modifications at position 1 and 5 for increased lipophilicity 
 
Compounds Sequence Inhibition of Threshold 
Platelet Aggregation 
  µM ± S.E.M 
27 (FM19) D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2 16 ± 4 
43 D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH-Me 21 ± 9 
44 D-Arg-Oic-Pro-D-Ala-D-Phe(2,4-Me)-NH2 100 ± 11 
45 D-Arg-Oic-Pro-D-Ala-Phe(2,4-Me)-NH2 28 ± 10 
46 D-Arg-Oic-Pro-D-Ala-D-Phe(3,4-Me)-NH2 750* 
47 D-Arg-Oic-Pro-D-Ala-Phe(3,4-Me)-NH2 62 ± 19 
48 D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH-Et 5 ± 0.4 
49 Arg(Me)-Oic-Pro-D-Ala-Phe(p-Me)-NH2 833 ± 167 
50 Arg(Me)-Pro-Oic-D-Ala-Phe(p-Me)-NH2 NE* 
51 D-Arg(Me)-Oic-Pro-D-Ala-Phe(p-Me)-NH2 1,000* 
Data presented are the mean ± S.E.M. of n > 3 independent experiments. The values given represent the 
minimal concentration of peptide necessary to inhibit 100 % of threshold γ -thrombin-induced platelet 
aggregation (IC100). * These data are presented as 1 experiment not as the mean of multiple experiments.  
 
 
The data suggest that the addition of alkyl moieties to either the aromatic ring in 
position 5 or the amide of the C-terminus are well tolerated. Compounds 43 and 45 
showed negligible changes in activity when compared to 27 (1.3 and 1.8-fold decrease, 
respectively), and both possessed an additional methyl group. However, the most 
promising compound in this series was peptide 48 (D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-
NH-Et), which was 3.2-fold more potent than the previous lead, compound 27. The 
 57
alkylation of the amide group of the C-terminus with the ethyl moiety produced a 5 µM 
inhibitor of platelet aggregation and has provided a site at which longer aliphatic and 
aromatic groups can be added to modulate the lipophilicity and possibly improve the 
intestinal absorbance of the analogs.  
This series has also provided information on requirements for position 1. 
Compounds 49 thru 51 were designed to explore whether any modifications to the 
guanidino group could be tolerated. Previously synthesized analogs with complete 
removal of the guanidino moiety (D-citrulline and D-lysine at position 1) produced 
inactive analogs. By alkylating the Nω of the arginine residue, we were aiming to 
maintain activity due to the small size of the substituent. Unfortunately, all peptides with 
this modification were inactive in the platelet aggregation assay as shown in Table 10. 
The results were not surprising since the crystal structure of compound 27 bound to the 
active site of thrombin clearly showed that the alignment between the D-arginine residue 
and Asp189 (Figure 14) was ideal. Compound 51 was inserted into the active site and the 
interaction of Nω-Methyl-D-arginine with Asp189 is highlighted in the computational 





















Figure 18: Compound 51 docked to the active site of thrombin highlighting 
the interaction of Nω-Methyl-D-arginine (left side in green) and Asp189. On the right, 27 is  
displayed in blue for comparison. 
 
 
In order to experimentally examine whether the changes in the platelet 
aggregation results are due to variations in the interaction with the active site of 
thrombin, the inhibition constant (Ki) for several of the new analogs was determined as 
previously described in Chapter III. The Ki values of the peptide analogs correlated with 
the results of the platelet aggregation assay as shown in Table 11. For instance, 
compound 51, which was inactive in the physiological assay, had significantly larger Ki 
value (409.5 ± 144 µM) than the new lead (compound 48, Ki = 2.1 ± 0.4 µM). This 
suggests that the peptides are modulating platelet aggregation through their ability to 
interact with thrombin. Furthermore, compound 48 is 3-fold better inhibitor of thrombin 
than 27, which precisely corresponds to the result for the platelet aggregation assay (3.2-
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fold improvement over 27). This series has provided further confirmation that our 
analogs are acting as direct thrombin inhibitors.              
TABLE 11 
 
Effect of peptide analogs on enzymatic activity of thrombin. 
 
Compounds Sequence Ki




TH146 D-Arg-Oic-Pro-Gly-Phe-NH2 91.9 ± 7 140 ± 20 
27 D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2 5.9 ± 1 16 ± 4 
29 D-Arg-Oic-Pro-D-Ser-Phe(p-Me)-NH2 6.9 ± 0.9 13 ± 6 
43 D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH-Me 5.2 ± 0.7 21 ± 9 
44 D-Arg-Oic-Pro-D-Ala-D-Phe(2,4-DiMe)-NH2 25* 100 ± 11 
45 D-Arg-Oic-Pro-D-Ala-Phe(2,4-DiMe)-NH2 5 ± 0.8 28 ± 10 
48 D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH-Et 2.1 ± 0.4 5 ± 0.4 
51 D-Arg(Me)-Oic-Pro-D-Ala-Phe(p-Me)-NH2 409.5 ± 144 1,000* 
The enzymatic activity assay was performed as described under Materials and Methods. The data presented 
are mean ± standard deviation of at least three independent experiments. *The result reported was based on 
a single experiment due to small amount of pure material available for testing. 
 
 
We are currently awaiting the stability and bioavailability results that will 
determine if we have enhanced the lipophilicity and absorbance profile of our lead 
compound by introducing these small changes to its structure. Dr. John Hilfinger is 
examining the stability, LogD values, and oral bioavailability of a number of analogs 
including 48, which has the potential of maintaining the stability and bioavailability of 27 
since it has the same amino acid composition. We are hopeful that the additional ethyl 
group at the C-terminus may lead to improved absorption due to the possible increase in 
lipophilicity.  
The absorption experiments are underway and the preliminary results suggest that 
the small modifications made to the sequence of our lead compound can modulate 
absorption in animal models. As postulated above, compound 48 displayed similar 
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absorption to analog 27. This data is particularly interesting since compound 48 










The aims set forth for this research project were accomplished through the use of a 
variety of approaches including several series of peptide analogs, biochemical and 
molecular biology techniques, in vivo and in situ pharmacokinetic studies, and crystal 
structure driven computational models. This dissertation emphasizes the benefits of using 
unnatural and/or modified amino acid residues substituted into the sequence of a naturally 
occurring peptide as a means of modulating activity against platelet aggregation. 
Particular analogs were identified that are both potent inhibitors of the physiological 
action as well as direct inhibitors of thrombin with desirable pharmacokinetic profiles. In 
addition, this dissertation describes the key structural features required for potency and 
suggests modifications that may lead to improved oral absorption in the gastrointestinal 
tract. Peptides 27 and 48 show promise to become the first orally administered 
anticoagulant with action through the direct inhibition of thrombin.  
 Several trends were observed in the structure activity relationship studies 
described in Chapter II. These series of peptides were synthesized with the aim of 
inhibiting thrombin mediated platelet aggregation. The fourth position of the peptide 
analogs of D-Arg-Oic-Pro-Gly-Phe has a preference for D-amino acids, but is relatively 
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indiscriminant in regards to the actual amino acid residue and its side chain properties. 
The presence of an aromatic ring on the side chain of the amino acid in position 5 was 
preferred over all other amino acid side chains, with Phe(p-Me) displaying the best 
activity thus far. In compound 27, (D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2), we have 
developed a 16 µM inhibitor of thrombin-induced platelet aggregation, which represents 
an order of magnitude improvement over previous RPPGF-related inhibitors.  
 Further studies were then performed to elucidate the mechanism of action of the 
lead peptide and its analogs. Like RPPGF and TH146, compound 27 also displays direct 
inhibition of thrombin as evident by the results of the coagulation assays reported in 
Chapter II. The fact that this lead compound was a 10-20 fold better inhibitor of the 
clotting abilities of thrombin than TH146 indicates that this peptide acts as a direct 
thrombin inhibitor by interacting with the active site of the enzyme. Furthermore, 27 was 
approximately 16-fold more potent at inhibiting the catalytic activity of thrombin as 
determined by the lower Ki value (5.9 µM). The same outcome was observed in cells, 
since 27 was a potent inhibitor of calcium mobilization in normal human cells. Calcium 
influx in platelets is a downstream signal of thrombin induced platelet activation and 
aggregation.  
 The data thus far suggests that compound 27 is a potent direct thrombin inhibitor 
in vitro and in cells. However, previously reported work by Hasan et al.[80, 81, 92] 
suggested that RPPGF and TH146 inhibited platelet aggregation by both interacting with 
the active site of thrombin and by binding directly to the extracellular domain of PAR1. 
In order to address this hypothesis, a competition-binding experiment to measure whether 
compound 27 interferes with the binding of 15 µM RPPGFK-biotin to the exodomains of 
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PAR1 and PAR4 was performed. The results did not completely support the hypothesis 
proposed by Hasan et al. Since compound 27 was 2-fold less potent than TH146 at 
inhibiting the binding of the labeled compound to the receptor, the results were 
suggestive of an interaction with the receptor, but the IC50 observed did not correlate with 
the physiological assay results. In the platelet aggregation assay, 27 was 7-fold more 
potent than TH146 suggesting that a different mechanism of action was modulating the 
anticoagulant activity of the peptide.  
 The recent elucidation of the crystal structure of analog 27 bound to the active site 
of thrombin by Dr. Enrico Di Cera provides complimentary data to confirm that the lead 
compound is a direct thrombin inhibitor (Chapter III). In the overlay computational 
studies performed by Katrina Lexa, compound 27 appears to align with hirudin-like 
analogs containing the sequence D-Phe-Pro-Arg. These compounds are characterized as 
potent inhibitors of the active site of thrombin, which is consistent with the biological 
data described in Chapter III. Many direct thrombin inhibitors have been developed, but 
they do not possess the pharmacokinetic characteristics for oral delivery. Therefore, in 
collaboration with TSRL, Inc. the pharmacokinetic profile of compound 27 was studied 
including its intestinal stability and oral bioavailability in rats. Since the peptide contains 
mostly unnatural peptide bonds, it was very stable and was 12.7% available following in 
situ administration.  
 The promising results from the stability and bioavailability studies led to the 
design of a series of analogs with features aimed at improving the oral absorption of 
compound 27. The modifications made to the sequence of the lead compound were 
relatively small and conservative so as not to adversely affect the activity of peptide. 
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Initially the focus was to change the net charge of the peptide by acetylating the free N-
teminus and eliminating the guanidino moiety at position 1. Both modifications produced 
inactive analogs in the platelet aggregation assay suggesting that both are required for 
interaction with thrombin. Consequently, the focus shifted to the opposite end of the 
peptide and substituents were added to the aromatic ring of phenylalanine at position 5 
and to the amide group at the C-terminus. These modifications were well tolerated and a 
new lead compound was discovered. Compound 48 (D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-
NH-Et) has the same amino acid sequence as analog 27, but possesses an ethyl group at 
the amide of the C-terminus. This compound is a 3-fold more potent inhibitor of 
thrombin and platelet aggregation (Ki = 2.1 µM, IC100 = 5 µM) than is 27. 
 Since the sequence of the new lead peptide is the same as that of compound 27, it 
can be expected that the stability will remain constant. However, the additional ethyl 
group at the C-terminus has the potential to increase the lipophilicity of the molecule and 













MATERIALS AND METHODS 
 
PEPTIDES AND REAGENTS. Peptides were prepared by standard solid-phase peptide 
synthesis methods[109, 110]. Syntheses were done using Fast-Moc chemistry (activation 
with HBTU/HOBt) on a Applied Biosystems, Inc. Model 431A peptide synthesizer 
(Foster City, CA)[111]. The peptides were assembled on peptide amide linker polyethylene 
glycol polystyrene resin (PAL-PEG-PS resin) (Applied Biosystems, Foster City, CA), 
Rink amide resin (Advanced ChemTech, Louisville, KY), [3-({methyl-Fmoc-amino}-
methyl)-indol-1-yl] acetyl AM resin or [3-({ethyl-Fmoc-amino}-methyl)-indol-1-yl] 
acetyl AM resin (Novabiochem, San Diego, CA). The protected amino acids were 
obtained from Advanced ChemTech with side chain protecting groups including Pbf and 
Mtr for Arg, D-Arg and alkylated arginine derivatives, tBu for D-Ser and Tyr, Boc, for 
Lys, and Trt for Cys. Dde and biotin protected Lys along with 5-carboxyfluorescein (5-
FAM) labeling agent were purchased from Novabiochem. 
The following solvents used were HPLC grade: water, acetonitrile (CH3CN), 
methanol, iso-propanol and dichloromethane (DCM) (Fisher Scientific, Fair Lawn, NJ). 
Trifluoroacetic acid (TFA) used was Biograde (Pierce, Rockford, IL), DMF (anhydrous) 
(Sigma Aldrich, Milwaukee, WI) was saturated with N2, and pyridine (Sigma Aldrich) 
was distilled over ninhydrin. All other reagents and solvents were purchased from Sigma 
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Aldrich and were used without further purification. Reverse phase high performance 
liquid chromatography (RP-HPLC) solvents, prepared with HPLC grade TFA, were 
filtered and degassed prior to use. 1H-NMR spectra were recorded on a BrukerTM DRX-
500 spectrometer. NMR samples were dissolved in D2O (Sigma Aldrich) and spectra 
were taken at room temperature. Ion exchange chromatography was performed with 
DowexTM 50W x 8 resin (200-400 mesh, Sigma Aldrich) on a 32 x 2 cm column. TLC 
was performed with pre-coated TLC plates (2.5 x 7.5 cm, 250 µm silica gel thickness, 
Fluka). The following solvent systems were used: 3:1 Phenol-water (A) and 9:1 MeOH-
chloroform (B). Products were visualized with iodine vapor and/or 1% (w/v) ninhydrin in 
ethanol.  
 RP-HPLC was accomplished with C18 VydacTM columns: 0.46 x 25 cm for 
analytical RP-HPLC on Waters Alliance system, flow rate of 1.0 mL/min; 1.0 x 25 cm 
for semi-preparative RP-HPLC, flow rate of 4.7 mL/min; 2.5 x 22 cm for preparative RP-
HPLC, flow rate of 10 mL/min on Waters system. The solvent system consisted of 0.1% 
(w/v) TFA in acetonitrile (solvent B) and 0.1% (w/v) TFA in water (solvent A). Silica gel 
purification was performed on pre-packaged cartridges (KP-SilTM, 32-63 µM, 60Å silica) 
on a BiotageTM system. The pure peptides were freeze dried on a bench top SLC VirTisTM 
freeze dryer (VirTis, Gardiner, NY). Molecular weights were determined using ESI-MS 
(electron spray ionization) positive mode (ThermoFinnigan, San Jose, CA). 
 
GENERAL PROTOCOL FOR SOLID PHASE PEPTIDE SYNTHESIS. The 
syntheses were carried out with 0.25 mmol scale with 4-fold excess of amino acid residue 
and coupling reagents, unless otherwise specified. The synthesis cycle was initiated by 
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swelling the resin (0.25 mmol) in NMP followed by removal of the Fmoc group from the 
empty resin with neat piperidine, followed by extensive NMP washes and, subsequently, 
by coupling of Fmoc-protected amino acid (1 mmole) dissolved in HBTU in 0.5 M 
solution of HOBt in DMF along with additional NMP. The reaction was carried out in the 
presence of 2 M DIEA in NMP (Applied Biosystems)[111]. The activated amino acid 
reacted with the deprotected amino-terminus of the growing peptide chain. After 10 min 
of coupling, the resin was washed repeatedly with NMP and unreacted amino groups 
were acetylated using 10-fold excess of the capping solution (0.5 M acetic anhydride, 
0.125 M DIEA, and 0.015 M HOBt in NMP). This sequence of steps was repeated until 
the full-length, resin-bound, protected peptide was obtained. The resin was filtered, 
washed with DCM and ethyl alcohol and dried in vacuo. 
 
GENERAL METHOD FOR LOADING RINK AMIDE RESIN (FM55 and FM59). 
The first amino acid residue was loaded manually on to the resin for FM55 and FM59. 
The reactions were carried out in a fritted reaction vessel (Peptide International, 
Louisville, KY) and agitated on a WS-180˚ Glas-Col shaker. The resin (0.25 mmol, 0.33 
g) was swelled with DCM and washed with NMP. The resin was deprotected with 20% 
(v/v) piperidine in NMP, washed with NMP, and tested for free amino groups with 
ninhydrin test.  
 For FM55, 1 mmol (4-fold excess) of Fmoc-(3,4-Dimethylphenylalanine) was 
dissolved in 2.5 mL NMP and activated with 2.1 mL of 0.45 M HBTU/HOBt in DMF. 
The activated amino acid was transferred to the reaction vessel along with 0.34 mL 2M 
DIEA, and the reaction was allowed to proceed for 7 hrs. The coupling reaction was 
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monitored hourly by ninhydrin test. After completion of the coupling, the free amino 
groups of the resin were acetylated with capping solution composed of 19 mL acetic 
anhydride, 9 mL DIEA, and 6 mL 1M HOBt/DMF in total volume of 400 mL NMP. The 
resin was rinsed with NMP and DCM then dried in vacuo. FM59 was synthesized under 
the same protocol, but only 0.25 mmol of Nα-Z, Nω-Me, Mtr-D-Arg-OH (1-fold) was 
available for coupling to the resin. 
 
GENERAL PROTOCOL FOR CLEAVAGE AND DEPROTECTION. TFA/H2O 
/thioanisole/ethylenedithiol solution (9:0.5:0.25:0.25, v/v/v/v) was used to cleave the 
peptide from the resin and simultaneously remove the side chain protecting groups. The 
mixture was stirred for 2 hrs at room temperature then the peptide solution was filtered 
from the resin. The solvent was removed by rotary evaporation and the peptide was 
precipitated with cold anhydrous ethyl ether. Crude material was filtered, dried, analyzed 
by analytical RP-HPLC and purified by semi preparative reverse-phase high-performance 
liquid chromatography (RP-HPLC) to afford the target peptide. Purity was determined by 
analytical RP-HPLC and molecular weight confirmation was confirmed by ESI-MS.  
 
GENERAL METHOD FOR DISULFIDE CYCLIZATION OF PEPTIDES (FM13-
FM15). Linear disulfhydryl-containing peptide was dissolved in a 1% (v/v) AcOH in 
H2O solution (saturated with N2) at 5˚C (1 mg linear peptide/ mL aqueous AcOH 
solution). The pH of the peptide solution was raised to 8.5 with NH4OH, followed by the 
addition of 4 equivalents of potassium ferricyanide (K3Fe(CN)6). The reaction mixture 
was stirred for 1 min then the reaction was quenched by lowering the pH to 3.5 with 
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glacial acetic acid. The mixture was purified using semi preparative RP-HPLC to afford 
the disulfide cyclized peptide. 
 
GENERAL METHOD FOR DITHIOETHER CYCLIZATION OF PEPTIDES 
(FM13-FM15). Linear disulfhydryl peptide was added to DMF and maintained at 5˚ C 
under N2 atmosphere (0.1 mg linear peptide/mL DMF). Ten equivalents of potassium 
tert-butoxide (KOtBu) were added to the peptide solution, followed by 10 equivalents of 
Br-(CH2)2-Br. The reaction was quenched with 5 mL AcOH after 2 hrs and the solvent 
was removed in vacuo. The residue was dissolved in water, filtered and subjected to semi 
preparative RP-HPLC to afford the dithioether cyclized peptide. 
 
PEPTIDE CHARACTERIZATION. The purity of all final peptides was determined by 
analytical RP-HPLC with elution gradient of 0% to 70% solvent B in 70 min monitored 
at 230 nm. The purity of all peptides was ≥ 98% as analyzed by HPLC. Final product 
molecular weight was confirmed by ESI-MS. 
 
SYNTHESIS OF UNNATURAL AMINO ACIDS. 
 
Nα-Z,Nω-(Me, Mtr)-D-Arginine (Scheme 1)[103-105] (1) 
N,S-dimethylpseudouronium iodide salt (1a) 
3.1 mL of iodomethane (50 mmol) was added drop wise to a slurry of 4.5 g 1-methyl-2-
thiourea (50 mmol) in 30 mL acetone. After the initial reaction subsided, the mixture was 
refluxed for 10 min and 10 mL absolute ethanol was added. The solution was saturated 
 70
with hexane while hot. After cooling, the formed crystals were collected by filtration and 
dried to give 11.2 g of white powder (97% yield).  
Nω-Methyl-D-arginine (1b) 
1.7 g of D-ornithine (10 mmol) and 0.9 g of copper (II) acetate (5 mmol) were dissolved 
in 20 mL of 1:1 NH4OH-H2O then 2.3 g of N,S-dimethylpseudouronium salt (1a) (10 
mmol) was added to the mixture. The solution was stoppered and stirred for 24 hrs at 
room temperature. The copper mercaptide was filtered and washed with 1:2 NH4OH-
H2O. The blue filtrate was concentrated to 20 mL and loaded on a Dowex 50Wx8 column 
(200-400 mesh, H+ form, 50x2 cm). The column was washed with 200 mL of water 
followed by 200 mL 0.2 N NH4OH. The product was eluted with 300 mL 1 M NH4OH 
and its presence was determined by TLC (solvent system A, developed with 1% 
ninhydrin). The fractions were dried to give 1 g of pure material (49.5% yield) with 
structure confirmed by NMR[103]. 
Nα-benzyloxycarbonyl-Nω-D-methylarginine (Scheme 2)[106] (1c) 
0.96 g Nω-methyl-D-arginine (1b) (5.1 mmol) was dissolved in 0.05 N NaOH (9 mL) 
with stirring at 0˚C. Stirring was continued on ice as 0.93 mL of benzyl chloroformate 
(6.6 mmol) was added along with 2 mL of 0.05 N NaOH in alternating portions. The pH 
of the mixture was maintained at 9 to 10. The reaction was allowed to proceed for 2 hrs 
(the pH will dropped to 7-7.5 during this time) then the solution was acidified to pH 3 
with 0.5 N HCl. The solution was filtered and extracted with ethyl acetate. The product 
was detected in the aqueous layer by TLC (solvent system B) and the solution was 
concentrated to 4 mL. The solution was loaded onto a silica gel column (KP-SilTM). The 
Product was purified using a 9:1 methanol-chloroform solvent system. The fractions 
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containing the product were combined, evaporated, and dried to give 1.2 g of desired 
product with molecular weight confirmed with ESI-MS. ESI-MS [M+H]+ = 323.5. 
Nα-Z- Nω-(Me, Mtr)- D-arginine (Scheme 2)[107] (1) 
0.8 g of Nα-benzyloxycarbonyl-Nω-D-methylarginine (1c) (2.8 mmol) was dissolved in 4 
N NaOH-acetone (4 mL-14 mL) and the solution was cooled on ice prior to the addition 
of 1.1 g 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (Mtr-Cl) (5 mmol) in 4 mL 
acetone. The solution was stoppered and stirred for 25 hrs at room temperature then 
acidified to pH 3 with 10% citric acid. The solvent was evaporated and extracted with 
ethyl acetate, the organic layer washed with saturated NaCl and dried over anhydrous 
magnesium sulfate. The filtrate was concentrated to an oily residue then reconstituted in 
MeOH and purified by semi-preparative RP-HPLC with gradient 30-50% solvent B in 60 
min. The fractions containing pure product were freeze dried to give 200 mg of white 
solid (13.3% yield). ESI-MS [M+H]+ = 535.4. 
 
Nω-Ethyl-D-arginine (Scheme 1)[103-105] (2) 
N-ethyl-S-methylpseudouronium iodide salt (2a) 
3.1 mL of iodomethane (50 mmol) was added drop-wise to a slurry of 5.2 g 1-ethyl-2-
thiourea (50 mmol) in 30 mL acetone. After initial reaction subsided, the mixture was 
refluxed for 10 min and 10 mL absolute ethanol was added. The solution was saturated 
with hexane while hot. Since no crystals formed after cooling, the solvent was evaporated 
to give 11.8 g of yellowish material (96.7% yield). The obtained solid was dissolved in 
30 mL of hot water in the presence of activated charcoal. After filtration, evaporation of 
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solvent and repeated treatment with ethyl ether, 4 g of pure material was recovered 
(32.8% yield).  
Nω-ethyl-D-arginine (2) 
1.7 g of D-ornithine (10 mmol) and 0.9 g of copper (II) acetate (5 mmol) were dissolved 
in 20 mL of 1:1 NH4OH-H2O, then 2.6 g of N-ethyl-S-methylpseudouronium salt (2a) 
(10 mmol) was added to the mixture. The solution was stoppered and stirred for 24 hrs at 
room temperature. The copper mercaptide was filtered and washed with 1:2 NH4OH-
H2O. The blue filtrate was concentrated to 20 mL and loaded on a Dowex 50Wx8 column 
(200-400 mesh, H+ form, 50x2 cm). The column was washed with 200 mL of water 
followed by 200 mL 0.2 N NH4OH. The product was eluted with 300 mL 1 M NH4OH 
and its presence was determined by TLC (solvent system A) and developed with 1% 
ninhydrin. The fractions were dried to give 1 g of pure material (49.5% yield) with 
structure of product confirmed by NMR[111]. 
 
Nω-2,4,5,6-tetrahydropyrimidyl-D-Arginine (Scheme 5)[103-105]  (3) 
2-(methylthio)-1,4,5,6-tetrahydropyrimidine iodide (3a) 
3.1 mL of iodomethane (50 mmol) was added drop-wise to a slurry of 5.8 g 3,4,5,6-
tetrahydropyrimidine thiol (50 mmol) in 30 mL acetone. After initial reaction subsided, 
the mixture was refluxed for 10 min and 10 mL absolute ethanol was added. The solution 
was saturated with hexane while hot. After cooling, the formed crystals were collected by 





1.7 g of D-ornithine (10 mmol) and 2.6 g of 2-(methylthio)-1,4,5,6-tetrahydropyrimidine 
iodide (3a) (10 mmol) were dissolved in 10 mL 2 N NaOH. The solution was stoppered 
and stirred for 9 days at room temperature. The solution was brought to neutral pH by 
addition of 6 N HCl and loaded on a Dowex 50Wx8 column (200-400 mesh, H+ form, 
50x2 cm). The column was washed with 200 mL of water followed by 200 mL 0.2 N 
NH4OH. The product was eluted with 300 mL 1 M NH4OH and its presence was 
determined by TLC (solvent system A) and developed with 1% ninhydrin. The fractions 
containing the product were dried to give 600 mg of pure material (28.6% yield) with 
structure of product confirmed by NMR[103]. 
 
Fmoc-DL-2,4-Dimethylphenylalanine (Scheme 3)[112] (4) 
diethyl acetamido-(2,4-dimethylbenzyl) malonate (4a)  
200 mL of absolute ethanol was transferred to a 500-mL round bottom flask and saturated 
with N2 for 30 min prior to the addition of 1.74 g of sodium (60 mmol). After all the 
sodium had reacted, 13 g of diethyl acetamidomalonate (60 mmol) was added and the 
mixture was stirred for 10 min. 8.8 mL of 2,4-dimethylbenzyl chloride (60 mmol) was 
added and reaction mixture was refluxed at 90˚ C for 2 hrs. The solution was cooled and 
filtered. The filtrate was evaporated in vacuo to obtain a white powder. The crude 
material was crystallized by triturating with 120 mL of warm 20% acetone in water. The 
crystals were filtered and dried overnight in vacuo to render 14.3 g of white powder 
(71.1% yield). The crude material was re-crystallized from 30 mL of warm benzene, then 
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filtered. The filtrate was cooled at 4˚ C for 2 hrs to promote crystal formation. The pure 
material was collected by filtration and dried to give 8.1 g (40.3% yield). 
DL-2,4-dimethylphenylalanine (4b) 
7.8 g of diethyl acetamido-(2,4-dimethylbenzyl) malonate (4a) (23.3 mmol) was 
dissolved in 35 mL of 6 N HCl and refluxed under N2 for 15 hrs. The solution was cooled 
at 4˚ C for 2 hrs then filtered and dried to render 4.9 g crude material. The white powder 
was dissolved in 60 mL of water and the solution was neutralized with 1 M Na2CO3 to 
pH 6.5. Precipitated material was collected by filtration to give 3 g of product. An 
additional 2.1 g of product was collected from the mother liquid after cooling overnight 
(93% yield).  
Fmoc-DL-2,4-dimethylphenylalanine[108] (4) 
1.2 g of 2,4-dimethylphenylalanine (4b) (3.3 mmol) was added to a solution of 14 mL 
DMF and 20 mL acetone. The suspension was cooled in an ice bath for 10 min before the 
drop-wise addition of 14 mL of 10% NaHCO3 solution. Fmoc-OSu (2.6 g, 3.9 mmol) was 
added along with an additional 50 mL of DMF. The mixture was stirred vigorously 
overnight at room temperature. The solvent was evaporated followed by extraction with 
ethyl acetate, the organic layer was washed with saturated NaCl, and the ethyl acetate 
layer was dried over anhydrous magnesium sulfate. The filtrate was concentrated to a 
yellowish oil and dried in vacuo overnight to give a hard yellow solid. The product was 
suspended in 100 mL of chloroform then filtered to render 0.52 g of white powder 
(36.1% yield), 93.4% purity as determined through analytical RP-HPLC. Molecular 
weight was confirmed by ESI-MS ([M+1]+ = 438.2). 
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Fmoc-DL-2,3-Dimethylphenylalanine (Scheme 3) (5) 
Following the protocol described above, a colleague, Ping He, prepared this amino acid 
residue. Final product was a brownish oil weighing 1.2 g, which was used for the 
synthesis of FM55 without further purification. 
 
SYNTHESIS, PURIFICATION AND CHARACTERIZATION OF PEPTIDES. 
 
H-D-Arg-Oic-Pro-D-Gln-Phe-NH2 (#10, FM21) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.72 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 150 mg of crude peptide. A 40 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-30% 
solvent B in 60 min to afford 29.2 mg pure peptide with elution time of 22.3 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 697.5.    
 
H-D-Arg-Oic-Pro-D-Abu-Phe-NH2 (#11, FM24) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.74 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 140 mg of crude peptide. A 39 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
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40% solvent B in 60 min to afford 29.4 mg pure peptide with elution time of 27.2 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
H-D-Arg-Oic-Pro-D-Orn-Phe-NH2 (#12, FM25) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.79 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 140 mg of crude peptide. A 38.2 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-30% 
solvent B in 60 min to afford 31.8 mg pure peptide with elution time of 21.4 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 683.5.    
 
H-D-Arg-Oic-Pro-D-Nle-Phe-NH2 (#13, FM26) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.78 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 130 mg of crude peptide. A 39.7 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 28.6 mg pure peptide with elution time of 32.1 min (0-





H-D-Arg-Oic-Pro-D-Ala-Phe(p-F)-NH2 (#17, FM28) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 90 mg of crude peptide. A 30.5 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 23.9 mg pure peptide with elution time of 26.3 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 658.5.    
 
H-D-Arg-Oic-Pro-Gly-Arg-NH2 (#22, FM3) 
0.31 g of Rink amide resin (0.8 mmol/g substitution) was used to synthesize the 
pentapeptide according to the general protocol. 0.5 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 127 mg of crude peptide. A 50.3 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-40% 
solvent B in 80 min to afford 22.4 mg pure peptide with elution time of 13.6 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 635.4.      
 
H-D-Arg-Oic-Pro-Gly-Tyr-NH2 (#23, FM4) 
0.31 g of Rink amide resin (0.8 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.45 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 140 mg of crude peptide. A 50 mg portion of 
 78
crude peptide was purified by semi-preparative RP-HPLC with gradient 0-30% solvent B 
in 60 min to afford 28.2 mg pure peptide with elution time of 18.2 min (0-70% solvent B 
in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 642.4.    
 
H-D-Arg-Oic-Pro-Gly-Phe(p-Me)-NH2 (#24, FM27) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.78 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 160 mg of crude peptide. A 45.3 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 35.4 mg pure peptide with elution time of 26.0 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 640.5.    
 
H-D-Arg-Oic-Pro-D-Ala-2-Nal-NH2 (#25, FM16) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.70 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 160 mg of crude peptide. A 40 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 22.6 mg pure peptide with elution time of 30.6 min (0-




H-D-Arg-Oic-Pro-D-Ala-Bip-NH2 (#26, FM18) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.74 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 180 mg of crude peptide. A 38 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-45% 
solvent B in 90 min to afford 32.4 mg pure peptide with elution time of 33.9 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 716.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2 (#27, FM19) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.74 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 170 mg of crude peptide. A 40 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-40% 
solvent B in 80 min to afford 39 mg pure peptide with elution time of 27.7 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-Cl)-NH2 (#28, FM20) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.75 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 130 mg of crude peptide. A 40 mg 
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portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-35% 
solvent B in 70 min to afford 21.2 mg pure peptide with elution time of 29.2 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 674.5.    
 
H-D-Arg-Oic-Pro-D-Ser-Phe(p-Me)-NH2 (#29, FM29) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.79 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 170 mg of crude peptide. A 42 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 32 mg pure peptide with elution time of 26.1 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 670.5.    
 
H-D-Arg-Oic-Pro-D-Asn-Phe(p-Me)-NH2 (#30, FM30) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.86 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 210 mg of crude peptide. A 41.1 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 27.3 mg pure peptide with elution time of 28.8 min (0-




H-D-Arg-Oic-Pro-D-Ala-Hfe-NH2 (#31, FM31) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.71 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 120 mg of crude peptide. A 40.8 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 25.6 mg pure peptide with elution time of 30.2 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-NH2)-NH2 (#32, FM32) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 170 mg of crude peptide. A 39.6 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-30% 
solvent B in 60 min to afford 32 mg pure peptide with elution time of 14.5 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 655.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-Br)-NH2 (#33, FM33) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.74 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 130 mg of crude peptide. A 39.9 mg 
 82
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 31.8 mg pure peptide with elution time of 32.6 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 718.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-tBu)-NH2 (#34, FM34) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 150 mg of crude peptide. A 39.8 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 15-
50% solvent B in 70 min to afford 18.6 mg pure peptide with elution time of 37.6 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 696.6.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-CN)-NH2 (#35, FM35) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.74 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 150 mg of crude peptide. A 40.2 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 33.7 mg pure peptide with elution time of 26.9 min (0-




H-D-Arg-Oic-Pro-D-Ala-Phe(p-I)-NH2 (#36, FM36) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.8 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 150 mg of crude peptide. A 42.8 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 35 mg pure peptide with elution time of 30.9 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 766.4.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(2-Me)-NH2 (#37, FM37) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 170 mg of crude peptide. A 44.3 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 20.9 mg pure peptide with elution time of 30.0 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(3-Me)-NH2 (#38, FM38) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.76 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 130 mg of crude peptide. A 42 mg 
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portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 27 mg pure peptide with elution time of 27.8 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-NO2)-NH2 (#39, FM39) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 150 mg of crude peptide. A 41.2 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 31.7 mg pure peptide with elution time of 25.1 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 685.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phg-NH2 (#40, FM40) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 170 mg of crude peptide. A 36.6 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 5-35% 
solvent B in 60 min to afford 16.7 mg pure peptide with elution time of 23.3 min (0-70% 




H-D-Arg-Oic-Pro-D-Ala-Phe(p-COOH)-NH2 (#41, FM52) 
0.34 g of Rink amide resin (0.75 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.46 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 130 mg of crude peptide. A 80 mg portion of 
the crude peptide was purified by semi-preparative RP-HPLC with gradient 10-40% 
solvent B in 60 min to afford 55.8 mg pure peptide with elution time of 23.9 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 684.4. 
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH-Me (#43, FM53) 
0.4 g of  [3-({methyl-Fmoc-amino}-methyl)-indol-1-yl] acetyl AM resin (0.63 mmol/g) 
was used to synthesize the N-methyl amide pentapeptide according to the general 
protocol. 0.57 g of peptide-resin was obtained from the solid phase peptide synthesis 
from which the peptide was cleaved according to the general cleavage and deprotection 
protocol to yield 150 mg of crude peptide. A 90 mg portion of the crude peptide was 
purified by semi-preparative RP-HPLC with gradient 15-45% solvent B in 60 min to 
afford 49.6 mg pure peptide with elution time of 31.6 min (0-70% solvent B in 70 min) 
on analytical RP-HPLC. ESI-MS [M+H]+ = 668.5. 
 
H-D-Arg-Oic-Pro-D-Ala-DL-Phe(2,4-DiMe)-NH2 (#44/#45, FM54) 
0.33 g of Rink amide resin (0.75 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.39 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
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cleavage and deprotection protocol to yield 130 mg of crude peptide. A 80 mg portion of 
the crude peptide was purified by semi-preparative RP-HPLC with gradient 15-50% 
solvent B in 70 min to afford two major products, #44/FM54a (10.8 mg) and #45/FM54b 
(28.1 mg), with elution times of 30.2 min and 33.2 min (0-70% solvent B in 70 min), 
respectively, on analytical RP-HPLC. ESI-MS [M+H]+ = 668.5. 
 
H-D-Arg-Oic-Pro-D-Ala-DL-Phe(2,3-DiMe)-NH2 (#46/#47, FM55) 
0.34 g of Rink amide resin (0.75 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. The first amino acid residue was pre-loaded on to the 
resin manually due to solubility issues of the residue. 0.46 g of peptide-resin was 
obtained from the solid phase peptide synthesis from which the peptide was cleaved 
according to the general cleavage and deprotection protocol to yield 175 mg of crude 
peptide. A 80 mg portion of the crude peptide was purified by semi-preparative RP-
HPLC with gradient 10-40% solvent B in 60 min to afford two major products, 
#46/FM55a (24.3 mg) and #47/FM55b (31.2 mg), with elution times of 26.8 min and 
29.8 min (0-70% solvent B in 70 min), respectively, on analytical RP-HPLC. ESI-MS 
[M+H]+ = 668.5. 
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH-Et (#48, FM56) 
0.33 g of  [3-({ethyl-Fmoc-amino}-methyl)-indol-1-yl] acetyl AM resin (0.83 mmol/g) 
was used to synthesize the N-ethyl amide pentapeptide according to the general protocol. 
0.4 g of peptide-resin was obtained from the solid phase peptide synthesis from which the 
peptide was cleaved according to the general cleavage and deprotection protocol to yield 
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170 mg of crude peptide. A 100 mg portion of the crude peptide was purified by semi-
preparative RP-HPLC with gradient 15-45% solvent B in 60 min to afford 78.3 mg pure 
peptide with elution time of 29.4 min (0-70% solvent B in 70 min) on analytical RP-
HPLC. ESI-MS [M+H]+ = 682.4. 
 
H-Nω-methyl-Arg-Oic-Pro-D-Ala-Phe(p-Me)-NH2 (#49, FM57) 
0.34 g of Rink amide resin (0.75 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.45 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 40 mg of crude peptide. All of the crude 
peptide was purified by semi-preparative RP-HPLC with gradient 10-40% solvent B in 
60 min to afford 10.8 mg pure peptide with elution time of 27.8 min (0-70% solvent B in 
70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 668.4. 
 
H-Nω-methyl-Arg-Pro-Oic-D-Ala-Phe(p-Me)-NH2 (#50, FM58) 
0.34 g of Rink amide resin (0.75 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.40 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 50 mg of crude peptide. All of the crude 
peptide was purified by semi-preparative RP-HPLC with gradient 10-40% solvent B in 
60 min to afford 11.3 mg pure peptide with elution time of 30.9 min (0-70% solvent B in 
70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 668.4. 
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H-Nω-methyl-D-Arg-Pro-Oic-D-Ala-Phe(p-Me)-NH2 (#51, FM59) 
0.34 g of Rink amide resin (0.75 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. The first amino acid residue was pre-loaded on to the 
resin manually due to small amount of amino acid used for the coupling reaction. 0.48 g 
of peptide-resin was obtained from the solid phase peptide synthesis from which the 
peptide was cleaved according to the general cleavage and deprotection protocol to yield 
200 mg of crude peptide. Since the last amino acid in the sequence was protected with the 
Cbz group, the crude material was treated for 30 min with 33% HBr in acetic acid (2 mL 
HBr and 4 mL acetic acid) in order to remove the protecting group. A 150 mg portion of 
the crude peptide was purified by semi-preparative RP-HPLC with gradient 10-50% 
solvent B in 80 min to afford 81.3 mg of pure peptide with elution time of 31.6 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 668.5. 
 
H-D-Arg-Oic-Pro-D-Phe-2-Nal-NH2 (#52, FM7) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.56 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 100 mg of crude peptide. A 50 mg portion of 
crude peptide was purified by semi-preparative RP-HPLC with gradient 0-50% solvent B 
in 100 min to afford 27.4 mg pure peptide with elution time of 38.2 min (0-70% solvent 




H-D-Arg-Oic-Pro-D-Ser-2-Nal-NH2 (#53, FM8) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.61 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 86 mg of crude peptide. A 32.1 mg portion of 
crude peptide was purified by semi-preparative RP-HPLC with gradient 0-40% solvent B 
in 120 min to afford 15.8 mg pure peptide with elution time of 29.6 min (0-70% solvent 
B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 706.5.    
 
H-D-Arg-Oic-Pro-D-Thr-2-Nal-NH2 (#54, FM9) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.60 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 80 mg of crude peptide. A 33.6 mg portion of 
crude peptide was purified by semi-preparative RP-HPLC with gradient 10-40% solvent 
B in 120 min to afford 22.0 mg pure peptide with elution time of 30.8 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 720.4 
 
H-D-Arg-Oic-Pro-D-His-2-Nal-NH2 (#55, FM10) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.63 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 110 mg of crude peptide. A 30.6 mg portion 
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of crude peptide was purified by semi-preparative RP-HPLC with a gradient of 10-40% 
solvent B in 120 min to afford a mixture of the two major peaks since they overlapped 
due to larger quantity used in the purification. Consequent, I decided to purify a second 
batch of 15.8 mg with the same gradient that afforded only trace amounts of pure 
material. Another 3 runs were performed in order to produce 11.4 mg pure peptide with 
elution time of 27.2 min (0-70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS 
[M+H]+ = 757.5.  
 
H-D-Arg-Oic-Pro-β-Ala-2-Nal-NH2 (#56, FM11) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.61 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 100 mg of crude peptide. A 34.9 mg portion 
of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-40% 
solvent B in 120 min to afford 18.2 mg pure peptide with elution time of 29.5 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 690.5. 
 
H-D-Arg-Oic-Pro-D-Gln-2-Nal-NH2 (#57, FM6) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.69 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 100 mg of crude peptide. A 30.7 mg portion 
of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-40% solvent 
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B in 120 min to afford 9.7 mg pure peptide with elution time of 28.1 min (0-70% solvent 
B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 747.5.    
 
Ac-D-Arg-Oic-Pro-Gly-Phe-NH2 (#58, FM5) 
0.31 g of Rink amide resin (0.8 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol with additional final capping step using solution 
composed of 19 mL acetic anhydride, 9 mL DIEA, and 6 mL 1M HOBt/DMF in total 
volume of 400 mL NMP in order to acetylate the amino terminus of the peptide. 0.45 g of 
peptide-resin was obtained from the solid phase peptide synthesis from which the peptide 
was cleaved according to the general cleavage and deprotection protocol to yield 145 mg 
of crude peptide. A 52.5 mg portion of crude peptide was purified by semi-preparative 
RP-HPLC with gradient 0-35% solvent B in 70 min to afford 29.0 mg pure peptide with 
elution time of 25.9 min (0-70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS 
[M+H]+ = 668.4.    
  
H-D-Arg-Oic-Cys-Gly-Phe-Cys-NH2 (FM13(SH2)) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the peptide according to 
the general protocol. 0.66 g of peptide-resin was obtained from the solid phase peptide 
synthesis from which the peptide was cleaved according to the general cleavage and 
deprotection protocol to yield 79.1 mg of crude peptide. All of the crude material was 
purified by semi-preparative RP-HPLC with gradient 0-40% solvent B in 120 min to 
afford 9.8 mg pure peptide with elution time of 28.6 min (0-70% solvent B in 70 min) on 
analytical RP-HPLC. ESI-MS [M+H]+ = 735.3. Unfortunately the amount of pure 
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material was not sufficient to carry out the subsequent cyclization reaction and a new 
synthesis was attempted with a double couple, double deprotection protocol to improve 
the yield.      
   
H-D-Arg-Oic-Cys-Gly-Phe-Cys-NH2 (FM13(SH2)DC) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the peptide according to 
the general protocol. 0.70 g of peptide-resin was obtained from the solid phase peptide 
synthesis incorporating the double couple, double deprotection protocol. This protocol 
consists two individual rounds of deprotection of the resin/peptide-resin and coupling 
with each amino acid residue to maximize the yield. The peptide was cleaved from the 
resin according to the general cleavage and deprotection protocol to yield 95 mg of crude 
peptide. All of the crude material was purified by semi-preparative RP-HPLC with 
gradient 10-40% solvent B in 90 min to afford 16.2 mg pure peptide with elution time of 
28.6 min (0-70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 735.3. 
 
H-D-Arg-Oic-c[Cys-Gly-Phe-Cys]-NH2 (#59, FM13(SS)) 
The linear peptide (22.6 mg) produced from the single and double couple syntheses 
(FM13(SH2) and FM13(SH2)DC) was subjected to cyclization with K3Fe(CN)6 
according to the general disulfide cyclization protocol. The cyclic peptide was purified by 
semi-preparative RP-HPLC to afford 14.1 mg (62.4%) of FM13(SS), 99% pure as 
determined by analytical RP-HPLC with elution time of 24 min (0-70% solvent B in 70 




In order to generate enough material to run the dithioether cyclization reaction, the 
synthesis of FM13(SH2) was repeated for a third time. A new resin was used with an 
extended linker, PAL-PEG-PS amide resin (0.41 mmol/g). 0.61 mg of resin was used to 
synthesize the peptide according to the double couple, double deprotection protocol. 0.76 
g of peptide-resin was obtained from the solid phase peptide synthesis from which the 
peptide was cleaved according to the general cleavage and deprotection protocol to yield 
80 mg of crude peptide. All of the crude material was purified by semi-preparative RP-
HPLC with gradient 0-40% solvent B in 120 min to afford 39.8 mg pure peptide with 
elution time of 28.6 min (0-70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS 
[M+H]+ = 735.3. 
 
H-D-Arg-Oic-c[Cys-Gly-Phe-Cys]-NH2 (#60, FM13(S-Et-S)) 
FM13(SH2)DC/PEG (25 mg) was reacted with 1,2-dibromomethane in the presence of 
KOtBu as described in the general protocol for dithioether cyclization. The cyclic peptide 
was purified by semi-preparative RP-HPLC to afford 9 mg (35%) of FM13(S-Et-S), 97% 
pure as determined by analytical RP-HPLC with elution time of 31 min (0-70% solvent B 
in 70 min). ESI-MS [M+H]+ = 761.4. 
 
H-D-Arg-Cys-Pro-Gly-Phe-Cys-NH2 (FM14(SH2)) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the peptide according to 
the general protocol. 0.66 g of peptide-resin was obtained from the solid phase peptide 
synthesis from which the peptide was cleaved according to the general cleavage and 
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deprotection protocol to yield 70 mg of crude peptide. All of the crude material was 
purified by semi-preparative RP-HPLC with gradient 0-30% solvent B in 90 min to 
afford 26.1 mg pure peptide with elution time of 20.4 min (0-70% solvent B in 70 min) 
on analytical RP-HPLC. ESI-MS [M+H]+ = 681.4. Unfortunately the amount of pure 
material was not enough to carry out the both cyclization reaction and a new synthesis 
was attempted with the new resin and double couple, double deprotection protocol to 
improve the yield.      
 
H-D-Arg-Cys-Pro-Gly-Phe-Cys-NH2 (FM14(SH2)DC/PEG) 
In order to generate enough material to run the dithioether cyclization reaction, the 
synthesis of FM14(SH2) was repeated for a third time. A new resin was used with an 
extended linker, PAL-PEG-PS amide resin (0.41 mmol/g). 0.61 mg of resin was used to 
synthesize the peptide according to the double couple, double deprotection protocol. 0.65 
g of peptide-resin was obtained from the solid phase peptide synthesis from which the 
peptide was cleaved according to the general cleavage and deprotection protocol to yield 
85 mg of crude peptide. All of the crude material was semi-purified by preparative RP-
HPLC with gradient 0-30% solvent B in 90 min to afford 20.8 mg pure peptide with 
elution time of 20.4 min (0-70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS 
[M+H]+ = 681.4. 
 
H-D-Arg-c[Cys-Pro-Gly-Phe-Cys]-NH2 (#61, FM14(SS)) 
The linear peptide (21 mg) was subjected to cyclization with K3Fe(CN)6 according to the 
general disulfide cyclization protocol. The cyclic peptide was purified by semi-
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preparative RP-HPLC to afford 7.3 mg (34.8%) of FM14(SS), 99% pure as determined 
by analytical RP-HPLC with elution time of 17.6 min (0-70% solvent B in 70 min). ESI-
MS [M+H]+ = 679.3. 
 
H-D-Arg-c[Cys-Pro-Gly-Phe-Cys]-NH2 (#62, FM14(S-Et-S)) 
FM14(SH2)DC/PEG (27.8 mg) was reacted with 1,2-dibromomethane in the presence of 
KOtBu as described in the general protocol for dithioether cyclization. The cyclic peptide 
was purified by semi-preparative RP-HPLC to afford 9.2 mg (32%) of FM14(S-Et-S), 
99% pure as determined by analytical RP-HPLC with elution time of 26.7 min (0-70% 
solvent B in 70 min). ESI-MS [M+H]+ = 707.4. 
 
H-Cys-D-Arg-Oic-Pro-Gly-Phe-Cys-NH2 (FM15(SH2)) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the peptide according to 
the general protocol. 0.72 g of peptide-resin was obtained from the solid phase peptide 
synthesis from which the peptide was cleaved according to the general cleavage and 
deprotection protocol to yield 110 mg of crude peptide. All of the crude material was 
purified by semi-preparative RP-HPLC with gradient 0-30% solvent B in 90 min to 
afford 48.6 mg pure peptide with elution time of 25.9 min (0-70% solvent B in 70 min) 
on analytical RP-HPLC. ESI-MS [M+H]+ = 832.5. 
 
H-c[Cys-D-Arg-Oic-Pro-Gly-Phe-Cys]-NH2 (#63, FM15(SS)) 
The linear peptide (22.2 mg) was subjected to cyclization with K3Fe(CN)6 according to 
the general disulfide cyclization protocol. The cyclic peptide was purified by semi-
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preparative RP-HPLC to afford 12.3 mg (55.4%) of FM15(SS), 100% pure as determined 
by analytical RP-HPLC with elution time of 24.3 min (0-70% solvent B in 70 min). ESI-
MS [M+H]+ = 830.4. 
 
H-c[Cys-D-Arg-Oic-Pro-Gly-Phe-Cys]-NH2 (#64, FM15(S-Et-S)) 
The linear peptide (20.8 mg) was reacted with 1,2-dibromomethane in the presence of 
KOtBu as described in the general dithioether cyclization protocol. The cyclic peptide 
was purified by semi-preparative RP-HPLC to afford 8.3 mg (49.4%) of FM15(S-Et-S), 
98% pure as determined by analytical RP-HPLC with elution time of 26.1 min (0-70% 
solvent B in 70 min). ESI-MS [M+H]+ = 857.4. 
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-Nε-biotinyl-Lys-NH2 (27K-biotin, FM42) 
0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the peptide 
according to the general protocol. 0.86 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 190 mg of crude peptide. All of crude peptide 
was purified by semi-preparative RP-HPLC with gradient 10-40% solvent B in 60 min to 
afford 111.8 mg pure peptide with elution time of 29.4 min (0-70% solvent B in 70 min) 
on analytical RP-HPLC. ESI-MS [M+H]+ = 1008.6.    
 
H-D-Arg-Pro-Oic-D-Ala-Phe(p-Me)-Nε-5-FAM-Lys-NH2 (27K-FAM, FM61) 
0.34 g of Rink amide resin (0.75 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.44 g of peptide-resin was obtained from the solid 
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phase peptide synthesis. In order to introduce the lysine with the fluorophore, 5-
carboxyfluorescein (5-FAM), the Dde protecting group on the lysine was removed by 
treating the resin with 2% hydrazine in DMF for 30 min. Excess 5-FAM (310 mg, 8-fold 
excess) was dissolved in 1.3 mL of DMF then activated by DIC (137 µL, 0.88 mmol) and 
HOBt (135 mg, 0.88 mmol). The activated fluorophore was added to the resin and the 
reaction allowed to proceed for 2 hrs. The resin was washed with 20% piperidine in DMF 
(v/v) until the solution was free of excess fluorophore (approximately 45 min). The 
labeled peptide was cleaved according to the general cleavage and deprotection protocol 
to yield 170 mg of crude peptide. All of the crude peptide was dissolved in MeOH and 
purified by semi-preparative RP-HPLC with gradient 25-55% solvent B in 60 min to 
afford 67.4 mg pure peptide with elution time of 38.5 min (0-70% solvent B in 70 min) 
on analytical RP-HPLC. ESI-MS [M+H]+ = 1140.5. All of the above reactions were 
carried out in complete darkness due to the light sensitivity of the fluorophore. 
 
H-D-Arg-Oic-Pro-D-Asn-Dpa-NH2 (FM12) 
0.5 g of Rink amide resin (0.5 mmol/g) was used to synthesize the pentapeptide 
according to the general protocol. 0.67 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 90 mg of crude peptide. A 30.3 mg portion of 
crude peptide was purified by semi-preparative RP-HPLC with gradient 0-40% solvent B 
in 80 min to afford 18.0 mg pure peptide with elution time of 29.6 min (0-70% solvent B 




0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.71 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 150 mg of crude peptide. A 41 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 29.4 mg pure peptide with elution time of 23.9 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 646.4.    
 
H-D-Arg-Oic-Pro-D-Dab-Phe-NH2 (FM22) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.78 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 100 mg of crude peptide. A 44 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-30% 
solvent B in 60 min to afford 29.6 mg pure peptide with elution time of 21.9 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 655.5.    
 
H-D-Arg-Oic-Pro-D-Dap-Phe-NH2 (FM23) 
0.61 g of PAL-PEG-PS amide resin (0.41 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.75 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 130 mg of crude peptide. A 35.9 mg 
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portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 0-30% 
solvent B in 60 min to afford 28.6 mg pure peptide with elution time of 21.3 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 669.5.    
 
H-D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-Lys-NH2 (FM41) 
0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the peptide 
according to the general protocol. 0.76 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 230 mg of crude peptide. A 100 mg portion 
of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-40% 
solvent B in 60 min to afford 86 mg pure peptide with elution time of 24.8 min (0-70% 
solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 782.6.    
 
H-Trp-Oic-Pro-D-Ala-Phe(p-Me)-NH2 (FM49) 
0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the peptide 
according to the general protocol. 0.74 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 110 mg of crude peptide. A 30 mg of the 
crude peptide was purified by semi-preparative RP-HPLC with gradient 15-50% solvent 
B in 70 min to afford 22.6 mg pure peptide with elution time of 40.1 min (0-70% solvent 





0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the peptide 
according to the general protocol. 0.78 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 90 mg of crude peptide. This peptide was not 
purified or characterized due to difficulties with solubility of the crude material. 
 
H-D-Glu-Oic-Pro-D-Ala-Phe(p-Me)-NH2 (FM51) 
1.0 g of PAL-PEG-PS amide resin (0.20 mmol/g) was used to synthesize the peptide 
according to the general protocol. 0.98 g of peptide-resin was obtained from the solid 
phase peptide synthesis from which the peptide was cleaved according to the general 
cleavage and deprotection protocol to yield 13.6 mg of crude peptide. All of the crude 
peptide was purified by semi-preparative RP-HPLC with gradient 10-40% solvent B in 
60 min to afford 8.4 mg pure peptide with elution time of 30.0 min (0-70% solvent B in 
70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 627.3. 
 
“SCRAMBLED” ANALOGS OF 27 
H-Phe(p-Me)-Oic-D-Arg-Pro-D-Ala-NH2 (FM43) 
0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 150 mg of crude peptide. A 100 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
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40% solvent B in 60 min to afford 87.8 mg pure peptide with elution time of 25.9 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.4.    
 
H-D-Ala-Pro-D-Arg-Oic-Phe(p-Me)-NH2 (FM44) 
0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 160 mg of crude peptide. A 100 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 40.4 mg pure peptide with elution time of 32.1 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
H-Pro-D-Ala-Phe(p-Me)-D-Arg-Oic-NH2 (FM45) 
0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.75 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 170 mg of crude peptide. A 56.8 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 49 mg pure peptide with elution time of 28.6 min (0-






0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.81 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 170 mg of crude peptide. A 55.5 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 43.7 mg pure peptide with elution time of 27.3 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
H-Pro-D-Arg-D-Ala-Phe(p-Me)-Oic-NH2 (FM47) 
0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.75 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 170 mg of crude peptide. A 57.5 mg 
portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 44.7 mg pure peptide with elution time of 29.8 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
H-Pro-D-Arg-Oic-Phe(p-Me)-D-Ala-NH2 (FM48) 
0.67 g of PAL-PEG-PS amide resin (0.38 mmol/g) was used to synthesize the 
pentapeptide according to the general protocol. 0.77 g of peptide-resin was obtained from 
the solid phase peptide synthesis from which the peptide was cleaved according to the 
general cleavage and deprotection protocol to yield 180 mg of crude peptide. A 54.6 mg 
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portion of crude peptide was purified by semi-preparative RP-HPLC with gradient 10-
40% solvent B in 60 min to afford 47.3 mg pure peptide with elution time of 31.5 min (0-
70% solvent B in 70 min) on analytical RP-HPLC. ESI-MS [M+H]+ = 654.5.    
 
PLATELET AGGREGATION ASSAY. Each peptide was examined for its ability to 
inhibit γ-thrombin-induced platelet aggregation of human platelet-rich plasma as 
described by Hasan et al. [81, 92]. Fresh whole blood from healthy human donors was 
collected into a syringe containing 3.8 % sodium citrate (1:9 citrate/blood). Whole blood 
was centrifuged at 180xg (Beckman GRP Centrifuge, Schaumburg, IL) for 10 min at 
room temperature to prepare platelet-rich plasma (PRP). Platelet-poor plasma (PPP) was 
prepared by centrifugation of PRP at 1,000×g for 20 min at room temperature or by 
centrifugation at 10,000×g for 2 min (Microcentrifuge E, Beckman Instruments, Palo 
Alto, CA). The platelets were counted on a Coulter counter (Model Z, Coulter 
Electronics, Hialeah, FL), and PRP was adjusted to a platelet count of 2.5×108 
platelets/mL, using PPP for dilution prior to all platelet aggregation studies. A Chronolog 
dual-channel aggregometer (Havertown, PA) was used to assess platelet aggregation by 
recording the increase in light transmittance through a stirred suspension of PRP 
maintained at 37°C in the cuvette. Variable concentrations of γ-thrombin (Haematologic 
Technologies, Essex Junction VT) were added to the PRP to determine the threshold 
concentration for maximal percent aggregation, i.e., the minimal concentration of the 
agonist to induce full aggregation and secretion. γ-Thrombin (Haematologic 
Technologies, Essex Junction, VT, ~3000 U/mg specific activity) was used for these 
studies because this form of the enzyme is unable to bind and proteolyze plasma 
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fibrinogen in plasma to produce a clot. Peptides were dissolved in fresh HEPES-Tyrodes 
buffer (pH = 7.40) and added at concentrations ranging from 5 µM to 1 mM to the PRP in 
the cuvette, allowing the baseline to stabilize. Platelet aggregation was initiated by the 
addition of threshold amounts of γ-thrombin (usually 30 to 70 nM for human platelets) 
determined for each donor on the day of assay. The aggregation was allowed to proceed 
for 5 minutes and the minimal concentration of each peptide to achieve 100 % inhibition 
of platelet aggregation (IC100) was determined. 
 
CALCIUM MOBILIZATION ASSAY. Each peptide was studied to determine its 
potential to inhibit α-thrombin-induced calcium mobilization in human fibroblast cells as 
previously described by Nieman et al.[92]. Normal human fibroblast cells were purchased 
from Clonetics (San Diego, CA) and were cultured according to the supplier’s 
instructions. The cytoplasmic concentration of free calcium was measured with Fura-2 
(Molecular Probes, Eugene, OR), a Ca2+ indicator. Cell suspensions in HEPES-Tyrodes 
buffer supplemented with 100 mM Ca2+ and 100 mM Mg2+ were incubated with 5 µM 
Fura for 60 minutes at room temperature. The excess indicator was removed by washing 
and centrifuging the cells three times with buffer. Aliquots of the cell suspensions were 
placed in a quartz cuvette that was positioned in a thermostatically controlled chamber at 
37°C in a fluorescence spectrophotometer (LS50B spectrofluorometer from PerkinElmer 
Life and Analytical Sciences. Boston, MA). Cells were treated with 0.5 to 2 nM of α-
thrombin to determine minimal amount required to achieve the maximum response. A 
variety of concentrations of the peptides were added to the cells suspension followed by 
the addition of threshold amounts of α-thrombin. The degree of inhibition by each 
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peptide was determined by calculating the change in the area under the curve produced 
by threshold α-thrombin using Winlab software (PerkinElmer Life and Analytical 
Sciences). The calcium mobilization data was expressed as percentage of inhibition as 
related to samples with α-thrombin alone. 
 
CLOTTING ASSAYS. The effect of each peptide on the activated partial 
thromboplastin time (APTT), prothrombin time (PT), and thrombin clotting time (TCT) 
was examined. The protocols used for the APTT, PT and TCT assays were previously 
described by Hasan et al.[80]. The APTT test was carried out by incubating 50 µL of 
normal human plasma (George King, Overland Park, KS) with 0-1mM of each peptide 
and 50 µL 1:2 APTT reagent (kaolin)-Tris buffer (Organon Teknika, Durham, NC) for 5 
min at 37˚ C. After incubation period, 50 µL of 30 mM CaCl2 was added and the time to 
clot formation was measured. 
 The PT test was performed by incubating 50 µL of normal human plasma with 0-
1mM of each peptide for 5 min at 37˚ C. Then 100 µL of PT reagent (thromboplastin) 
(Simplastin, Organon Teknika) and 100 µL of 30 mM CaCl2 were added and the time to 
clot formation was measured. The TCT experiment was carried out in a similar fashion 
with incubation followed by addition of 8 nM of human α-thrombin (1 U/mL) and the 
time to clot formation was then measured. All coagulant assays were performed in an 
Amelung KC4 coagulant analyzer (Sigma Aldrich). Values were considered significantly 
prolonged when the mean result at each concentration of peptide was p < 0.05 from the 
control on a nonpaired t test.  
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ENZYMATIC ACTIVITY EXPERIMENTS. An assay of enzymatic activity 
inhibition was employed to explore the interactions of our peptides with the active site of 
thrombin. The rate of cleavage of a chromogenic compound, Sar-Pro-Arg- p-nitroanilide, 
by both α- and γ-thrombin was monitored in the presence of 0, 20, 40, and 80 µM 
peptide. The experiment was carried out in triplactes with 2 nM α- and γ-thrombin 
(Haematologic Technologies), 1 mM Sar-Pro-Arg-p-nitroanilide (Sigma-Aldrich) (Km = 
138 µM), and 10 mM Tris-HCl, 0.15 M NaCl, pH 7.6 (Hasan et al., 2003). The same 
studies were carried out for several clotting factors to probe the ability of each peptide to 
inhibit other enzymes of the coagulation system as described by Nieman et al.[92]. To 
determine the inhibition of factor Xa (FXa) (Enzyme Research Laboratories Inc., South 
Bend, IN), 2 nM of enzyme was used to cleave 0.4 mM N-(p-Tosyl)-Gly-Pro-Arg-p-
nitroanilide. Inhibition of 3 nM factor XIa (FXIa) (Hematologic Technologies) cleavage 
of 0.6 mM L-pyro-Glu-Pro-Arg-p-nitroanilide (Diaphram, Franklin, OH) was also 
studied in presence and absence of each peptide. Additional experiments were carried out 
with 50 nM factor VIIa (FVIIa) with preformed complex of enzyme and 70 nM soluble 
recombinant tissue factor, sTF1-219, provided by Tom Girard (Monsanto, St. Louis, MO). 
The chromogenic substrate used in the FVIIa assay was 1.25 mM Spectrozyme fXa 
(methoxycarbonyl-D-cyclohexylglycyl-glycyl-arginine-p-nitroanilide)[113]. The same 
experiment was performed without the formation of the enzyme-tissue factor complex by 
incubation of the peptide with FVIIa prior to the addition of tissue factor. The Ki values 
were calculated from the Kiapp as described previously described by Bieth[114].  
EXPRESSION OF RECOMBINANT PROTEINS. The protocol for the cloning and 
expression of the recombinant exodomain of PAR1 was previously described by Hasan 
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et al.[81]. Purified recombinant exodomain of PAR1 and PAR4 was prepared from 1 liter 
cultures of Escherichia coli BLR(DE3) with the plasmid pET31b containing the 
corresponding cDNA that were grown to mid-log phase at 37 °C in Luria broth 
containing 1 mL carbenicilllin. This was followed by induction with 10 mL of 1 mM 
IPTG for 4 h. After induction, the bacteria were harvested by centrifugation (10 min, 
5000 × g) and the pellet was re-suspended in binding buffer (40 mM Tris–HCl and 500 
mM NaCl, pH 7.4) containing 8 mg/ml lysozyme and 5 µL of lysonase bioprocessing 
reagent. The bacterial extracts were then incubated for 15 min at room temperature. 
Bacterial lysates were centrifuged at 12000 × g for 10 min at 4˚ C and the pellet was re-
suspended in 12.5 mL of binding buffer containing 6 M guanidine HCl and 5 mM 
imidazole and purified with nickel-chelate affinity chromatography. This was followed 
by treatment with CNBr to remove the KSI fusion protein and the His tag according to 
the manufacturer’s protocol (Novagen, Madison, WI). The final recombinant proteins 
were further purified by HPLC. The integrity of the expressed PAR1 and PAR4 
exodomains were verified by MALDI-TOF mass spectrometry and ESI-MS. 
COMPETITION-BINDING EXPERIMENTS. Recombinant PAR1 and PAR4 
exodomains (rPAR4EC and rPAR4EC) were prepared as described above, and peptide 
binding was examined using the protocol previously described by Nieman et al.[92]. 
rPAR1EC (1 µg/well) in 0.1 M Na2CO3, pH 9.6, was bound to microtiter plate wells (F96 
CERT.MAXISORP, #439454; Nunc-Immuno Plate, Fisher Scientific, Chicago, IL) by 
incubation at 4°C overnight. After incubation, wells were washed three times with 10 mM 
NaH2PO4, 150 mM NaCl, pH 7.4, containing 0.05% Tween 20. After blocking the wells 
with 1% gelatin, the bound rPAR1EC was incubated with 20 µM RPPGFK-biotin 
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(Multiple Peptide Systems, Inc., San Diego, CA) in the presence or absence of various 
peptides 1 h at 37°C. After incubation, the wells were washed three times with 10 mM 
NaH2PO4, 150 mM NaCl, pH 7.4, containing 0.05% Tween 20 and the bound RPPGFK-
biotin was detected by using Immune-Pure streptavidin horseradish peroxidase conjugate 
(Pierce Chemical, Rockville, IL) and peroxidase-specific fast reacting substrate turbo-
3,3'5,5'-tetramethylbenzidine (turbo-TMB; Pierce Chemical) as described previously[115]. 
The color reaction was quenched by the addition of 1 M phosphoric acid, and the reaction 
was quantitated by measuring the absorbance at 450 nm in a Microplate auto reader 
EL311 (Bio-Tek Instruments, Winooski, VT). The same experimental protocol was 
applied to rPAR4EC to determine the ability of the peptides to bind to PAR4. 
 
DIRECT BINDING EXPERIMENT WITH D-Arg-Oic-Pro-D-Ala-Phe(p-Me)-
Lys(biotin)-NH2. Recombinant PAR1 exodomain (rPAR1EC) was prepared as described 
above, and peptide binding was examined using the protocol previously described by 
Nieman et al.[92].  rPAR1EC was incubated overnight at 4°C in 0.1 M Na2CO3, pH 9.6, to 
link the receptor to the wells of a 96-well microtiter plate (F96 CERT.MAXISORP, 
#439454; Nunc-Immuno Plate, Fisher Scientific). After incubation, the wells were 
washed five times with 10 mM NaH2PO4, 150 mM NaCl, pH 7.4, containing 0.05% 
Tween 20. The wells were then blocked with 0.2% bovine serum albumin in PBS with 
0.05% Tween 20 for one hour at 37° C. After blocking and washing of the wells, the 
bound rPAR1EC was incubated with 5-100 µM rOicPaF(p-Me)K-biotin in the presence 
and absence of 150-fold excess of unlabeled rOicPaF(p-Me) for 1 hr at 37° C. After 
incubation, the wells were washed three times with 10 mM NaH2PO4, 150 mM NaCl, pH 
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7.4, containing 0.05% Tween 20 and the bound rOicPaF(p-Me)K-biotin was detected by 
using Immune-Pure streptavidin horseradish peroxidase conjugate (Pierce Chemical) and 
peroxidase-specific fast reacting substrate turbo-3,3'5,5'-tetramethylbenzidine (turbo-
TMB; Pierce Chemical) as described previously[115]. The color reaction was stopped by 
the addition of 1 M phosphoric acid, and the reaction was quantitated by measuring the 
absorbance at 450 nm in a Microplate auto reader EL311 (Bio-Tek Instruments). 
 
PHARMACOKINETIC STUDIES. All animal studies were conducted by Mark 
Warnock in accordance with the Guide for the Care and Use of Laboratory Animals. 
Purpose-bred beagle dogs (8.8-12.5 kg) were anesthetized with intravenous 
administration of sodium pentobarbital (30 mg/kg), and anesthesia was maintained by 
intramuscular pentobarbital (90 mg) as needed. After tracheotomy, intubation, and 
positive pressure ventilation with room air using a Harvard respirator (Harvard 
Instruments, South Natick, MA), the right jugular vein and right femoral vein were 
cannulated for blood collection and drug administration, respectively. Arterial blood 
pressure was monitored from a cannulated right carotid artery with a blood pressure 
transducer (Gould Inc., Cardiovascular Product, Oxford, CA). Standard limb lead II of 
the electrocardiogram was recorded continuously and used to monitor heart rate. After a 
single intravenous administration of rOicPaF(p-Me) (4.4 mg/kg in 5 mL saline infused 
over 1 minute to each four dogs), blood samples were collected at 1, 5, 10, 15, 30, 25, 30, 
40, 60, 90, and 120 minutes by withdrawing 5 mL of blood into a syringe containing 3.8 
% sodium citrate (1:9, citrate/blood). The blood was centrifuged at 12,000g for 2 minutes 
at room temperature to prepare platelet-poor plasma that was stored in small aliquots at    
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-70°C until assay. The canine plasma samples in the pharmacokinetic studies were 
analyzed by HPLC chromatographic method using a C4 column as reported 
previously[80]. The pharmacokinetics were calculated using noncompartmental methods 
of Rowland and Tozer (1989).    
 
STABILITY ASSAYS. Simulated Intestinal Fluid Stability Assays. The stability of the 
peptide analogs were tested by Dr. John Hilfinger from TSRL, Inc. in simulated gastric 
and simulated intestinal fluid to ensure their integrity under these conditions.  For these 
assays, equal volumes of a stock solution of the analog to be tested (≥ 1 mg/mL in HPLC-
grade water) and 2 x simulated gastric fluid [70 mM NaCl and 6.4 mg/ml porcine 
mucosal pepsin (800-2500 units/mg of protein) in water, final pH ~ 1.2] or 2x simulated 
intestinal fluid (100 mM KH2PO4 with 20 mg/ml pancreatin, final pH 6.8) was mixed and 
incubated at 37o C in a shaking water bath.  Aliquots of 0.25 ml were removed at time 
points: 0, 1, 2, 3 and 4 h and prepared for LC/MS/MS analysis.   
 Homogenate Stability Assays. The perfusion buffer used in stability testing was 10 
mM MES (pH 6.5) containing 135 mM NaCl, and 5 mM KCl.  To collect intestinal 
perfusate from rats, male Sprague Dawley rats, 8 to 10 weeks old, weighing 250 to 350 g 
were fasted 15 to 18 hours with water given ad libitum.  Anesthesia was administered by 
intramuscular injection of pentobarbital/ketamine (40 mg/kg and 80 mg/kg, respectively).  
The rats were placed on a warming pad under a surgical lamp to maintain body 
temperature and jejunal intestinal segments were exposed through a midline, abdominal 
incision.  An approximately 20 cm segment of the jejunum (2 to 4 cm distal to the 
ligament of Treitz) was cannulated and the intestinal segments were perfused with 10 
mM MES (pH 6.5) containing 135 mM NaCl, and 5 mM KCl at a flow-rate of 0.5 ml/min 
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at 37°C using a constant infusion pump (Harvard Apparatus, South Natick, Mass.).  The 
collected perfusate was stored at -80oC until used for ex vivo stability studies.  After 
collection, the perfused intestinal segments were flushed with ice-cold 0.15 M KCl 
solution and the animal was euthanized and the jejunal intestinal segment detached.  The 
inner intestinal tissue layers were scraped out and homogenized in MES buffer (pH 6.5) 
at a ratio of 1 part of intestinal tissue to 5 parts buffer.  For liver homogenates, the liver 
was removed from the animals and prepared as described for the intestinal perfusates.  
Total protein content of the perfusate and the homogenates were determined using a 
BioRad protein assay kit.  The tissue homogenate samples were used immediately or 
rapidly frozen at -80oC until stability analysis. 
For the stability analysis, 0.7 mg of total protein (homogenates) was added to 0.6 
ml of 100 mM phosphate buffer (pH 6.5).  The reactions were initiated by adding the 
peptide analogs (~ 200 µM final) at 37oC.  0.2 ml aliquots were withdrawn at 
predetermined time intervals (e.g., 0, 5, 15, and 30 min).  The reaction was quenched by 
adding 0.2 ml of ice cold 10% trifluoroacetic acid (TFA).  The samples were centrifuged, 
filtered and analyzed for the intact peptide by LC/MS/MS.   
 
ORAL ABSORPTION STUDIES IN RATS USING DUODENAL 
ADMINISTRATION. All of the experiments described below were conducted at TSRL, 
Inc. Compounds were administered by intraduodenal injection and blood samples were 
taken at timed intervals over the course of ~ 4 hours. For comparative purposes between 
the different drugs, the dosing was performed at 10 mg/kg. For the dosing, on the day of 
the study, 3 fasted, male Sprague-Dawley rats were anesthetized and the femoral artery 
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catheterized following standard procedures. A midline incision was made to open the 
abdominal cavity, and the duodenal section of the intestine was isolated. Compounds 
were directly injected into the duodenum and 0.5 ml plasma samples were taken at timed 
intervals over the course of about 4 hours. 
 Rat plasma samples containing test peptides were analyzed by LCMS/MS. A solid 
phase extraction cartridge (HLB, 30 mg/1 cc, Waters) was activated with 1 mL of 
methanol and equilibrated with 1 mL of water. A 200 µL aliquot of rat plasma was 
acidified and loaded onto the cartridge. After washing with 1 mL of 5% methanol, the 
compounds were eluted with 1 mL of methanol. The solvent was evaporated under 
vacuum and the residue was reconstituted in 200 µL of mobile phase. Samples were 
analyzed using ESI-LCMS/MS (Micromass Quattro II) (Micromass, Beverly, MA), 
employing a HP1100 HPLC system (Hewlett Packard, CA). 10 µL of sample was 
purified with a C18, 5 µm, 50 mm X 2.2 mm (Higgins Analytical Inc., Mountain View, 
CA) using a mobile phase of 50:50 acetonitrile and water containing 0.1 % formic acid. 
Calibration curves were constructed by weighted (1/x) least square regression of peak 
area versus concentrations of the calibration standards.   
 
OCTANOL:WATER PARTITION COEFFICIENT. A 1 mg/ml aqueous solution of 
peptide analog in 50 mM phosphate buffer, pH = 7, was mixed with an equal volume of 
n-octanol and vigorously stirred for 4 hours at room temperature.  At the end of the 
incubation time, aliquots of the phases were analyzed for the peptide analogs.  The log 
DpH 7 was calculated by calculating the log of [drug]octanol /[drug]aq (pH 7).
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DOCKING STUDIES AND COMPUTATIONAL MODELS. The computational 
studies were carried out by Katrina Lexa as part of a rotation project in the Mosberg lab. 
Each peptide was initially built in MOE2006.08 to create analogs through sequence 
mutation of compound 27. Structure development was performed through use of the 
Build feature, after which each analog’s energy was calculated using PEOE charges. The 
crystal-structure derived analogs were docked into the binding pocket of thrombin using 
the active site defined by all receptor amino acids with the potential for electrostatic 
interaction with the ligand as determined by Dr. Enrico Di Cera and MOE2006.08. 
Ligand docking was performed to solvated thrombin through the Dock feature in 
MOE2006.08, using affinity ∆G as the scoring function and alpha triangle as the 
placement set. 
 
STATISTICAL ANALYSIS. Statistical comparisons between treatment groups used 
unpaired Student’s t test or the nonparametric Mann-Whitney signed rank test as needed 









































LIST OF AMINO ACIDS 
 
Abu    aminobutyric acid 
Ala (A)   alanine 
Arg  (R)   arginine 
Asn (N)   asparigine 
Asp  (D)   aspartic acid 
β-Ala    beta-alanine 
Bip    4,4’-biphenylphenylalanine 
Cys (C)   cysteine 
Dab    diaminobutyric acid 
Dap    diaminopropionic acid 
Dpa    diphenylalanine 
Gln (Q)   glutamine 
Glu (E)   glutamic acid 
Gly  (G)   glycine 
Hfe    homophenylalanine 
His  (H)   histidine 
Ile  (I)   isoleucine 
Leu (L)   leucine 
Lys (K)   lysine 
1-Nal    3-(1-naphthyl)-L-alanine 
2-Nal    3-(2-naphthyl)-L-alanine 
Nle    norleucine 
Oic    octahydroindole-2-carboxylic acid 
Orn    ornithine 
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Pro  (P)   proline 
Phe (F)   phenylalanine 
Phe(p-Br)   p-bromophenylalanine 
Phe(p-tBu)   p-tert-butylphenylalanine 
Phe(p-Cl)   p-chlorophenylalanine 
Phe(p-CN)   p-cyanophenylalanine 
Phe(p-COOH)   p-carboxyphenylalanine 
Phe(p-F)   p-fluorophenylalanine 
Phe(p-I)   p-iodophenylalanine 
Phe(2-Me)   2-methylphenylalanine 
Phe(3Me)   3-methylphenylalanine 
Phe(p-Me)   p-methylphenylalanine 
Phe(p-NH2)   p-nitrophenylalanine 
Phg    phenylglycine 
Sar    sarcosine, N-methylglycine 
Ser  (S)   serine 
Thi    thienylalanine 
Thr (T)   threonine 
Trp (W)   tryptophan 
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